

Highly Cited and Recent Papers on UVB and/or Vitamin D and Cancer

(826 Papers)



William B. Grant, Ph.D.
Sunlight, Nutrition, and Health Research Center (SUNARC)
P.O. Box 641603
San Francisco, CA 94164, USA
www.sunarc.org, wbgrant@infionline.net

Note: Abstracts are generally available through www.pubmed.gov. Also, an estimate of the number of citations can be obtained through Google Scholar: <http://scholar.google.com/> using the search terms such as: "author:A author:Einstein." The number of citations from Google Scholar (GS) will be somewhat different from those for the Institute of Scientific Information (ISI) (<http://www.isinet.com/>) since ISI looks at citations only from journal articles while GS includes a few from other sources. Unfortunately, ISI is only available through subscription, such as at a library or institution. (The number of citations were updated on Sept. 10, 2008 for the more highly cited papers dating back to 2002 and Nov, 2007 dating back to 1998.)

From <http://sciencewatch.com/about/met/thres-highlyctd/>, it appears as if I'm using a criterion of 1/3 the threshold for the top 1% of cited papers per year for clinical medicine in the 1990s. Therefore, this fraction should also be applied thereafter. The thresholds for the top 1 percentile through June 30, 2008 (posted September 1) from that URL are:

Year	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Threshold	190	183	176	165	156	139	126	107	84	62	36	14	3

I consider 1/3 of these values to be the threshold for highly cited papers on vitamin D and cancer.



112 papers (17 epub) (at this rate, 139 in year)

Abbas S, Linseisen J, Slinger T, Kropp S, Mutschelknauss E, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of postmenopausal breast cancer - results of a large case-control study. Carcinogenesis. 2008 Jan;29(1):93-9. (5 ISI)

Abbas S, Nieters A, Linseisen J, Slinger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. *Breast Cancer Res.* 2008 Apr 17;10(2):R31

Abbas S, Linseisen J, Slinger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. The gc2 allele of the vitamin d binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin d status. *Cancer Epidemiol Biomarkers Prev.* 2008 Jun;17(6):1339-43.

Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB; For the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum Vitamin D Concentration and Prostate Cancer Risk: A Nested Case-Control Study. *J Natl Cancer Inst.* 2008;11:796-804.

Atkinson SA. Vitamin D status and bone biomarkers in childhood cancer. *Pediatr Blood Cancer.* 2008 Feb;50(2 Suppl):479-82; discussion 486. Review.

Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. *Br J Haematol.* 2008 May 15. [Epub ahead of print]

Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. *Int J Cancer.* 2008 Jun 15;122(12):2699-706.

Baquet CR, Mishra SI, Commiskey P, Ellison GL, DeShields M. Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. *J Natl Med Assoc.* 2008 May;100(5):480-8.

Barreto SG, Ramadwar MR, Shukla PJ, Shrikhande SV. Vitamin D3 in operable periampullary and pancreatic cancer: perioperative outcomes in a pilot study assessing safety. *Pancreas.* 2008 Apr;36(3):315-7.

Beres S. Vitamin D: Cancer Prevention's Sunny Future? *J Natl Cancer Inst.* 2008;100: 292-297.

Berwick M, Lachiewicz A, Pestak C, Thomas N. Solar UV exposure and mortality from skin tumors. *Adv Exp Med Biol.* 2008;624:117-24.

Bikle DD. Vitamin D Receptor, UVR, and Skin Cancer: A Potential Protective Mechanism. *J Invest Dermatol.* 2008 Oct;128(10):2357-2361.

Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA. Vitamin D From Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-Defined Breast Cancer. *Am J Epidemiol.* 2008 Aug 27. [Epub ahead of print]

Boffetta P, Hel OV, Krickler A, Nieters A, Sanjosé SD, Maynadié M, Cocco PL, Staines A, Becker N, Font R, Mannetje AT, Goumas C, Brennan P. Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--a multicentre European case-control study. *Int J Epidemiol.* 2008 May 29. [Epub ahead of print]

Cannell J, Hollis B, Zasloff M, Heaney R. Diagnosis and treatment of vitamin D deficiency. *Expert Opin Pharmacother.* 2008 Jan;9(1):107-118.

Cantor I. Shedding Light on Vitamin D and Integrative Oncology. *Integr Cancer Ther.* 2008 Jun;7(2):81-9.

Carless MA, Kraska T, Lintell N, Neale RE, Green AC, Griffiths LR. Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. *Br J Dermatol.* 2008 Jul 19. [Epub ahead of print]

Chen TC. 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. *Anticancer Res.* 2008 Jul-Aug;28(4A):2015-7.

Cherniack EP, Florez H, Roos BA, Troen BR, Levis S. Hypovitaminosis D in the elderly: from bone to brain. *J Nutr Health Aging.* 2008 Jun-Jul;12(6):366-73.

Cheung E, Wadhera P, Dorff T, Pinski J. Diet and prostate cancer risk reduction. *Expert Rev Anticancer Ther.* 2008 Jan;8(1):43-50.

Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Gren S, Lukanova A, Sjodin H, Zeleniuch-Jacquotte A, Shore RE, Hallmans G, Toniolo P, Lundin E. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. *Cancer Lett.* 2008 Feb 18;260(1-2):209-215.

Colli JL, Grant WB. Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in United States. *Urology.* 2008 Mar;71(3):531-5.

Davis CD. Vitamin D and cancer: current dilemmas and future research needs. *Am J Clin Nutr.* 2008 Aug;88(2):565S-569S.

Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. *Int J Cancer.* 2008 Apr 15;122(8):1690-4.

Dixon KM, Mason RS. Vitamin D. *Int J Biochem Cell Biol.* 2008 Aug 3. [Epub ahead of print]

Egan KM, Signorello LB, Munro HM, Hargreaves MK, Hollis BW, Blot WJ. Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). *Cancer Causes Control.* 2008 Jun;19(5):527-35.

Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. *Int J Cancer.* 2008 May 1;123(2):430-435.

Everett PC. The prevalence of vitamin D deficiency and insufficiency in a hematology-oncology clinic. *Clin J Oncol Nurs.* 2008 Feb;12(1):33-5.

Fleet JC. Molecular actions of vitamin D contributing to cancer prevention. *Mol Aspects Med.* 2008 Aug 8. [Epub ahead of print]

Freedman DM. Commentary: The complexities of minimizing risks due to UV exposures. *Int J Epidemiol.* 2008;37:667-8.

Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG. Serum Levels of Vitamin D Metabolites and Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Cancer Epidemiol Biomarkers Prev.* 2008 Apr;17(4):889-94.

Freedman DM, Looker AC, Chang SC, Graubard BI. Response: Re: Prospective Study of Vitamin D and Cancer Mortality in the United States. *Journal of the National Cancer Institute* June 4 2008;100:827-8.

Ganry O, Lap tre-Ledoux B, Fardellone P, Dubreuil A. Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. *Eur J Epidemiol.* 2008;23(7):467-73.

Gapska P, Scott RJ, Serrano-Fernandez P, Huzarski T, Byrski T, K adny J, Gronwald J, G rski B, Cybulski C, Lubinski J, D bniak T. Vitamin D receptor variants and breast cancer risk in the Polish population. *Breast Cancer Res Treat.* 2008 Jun 29. [Epub ahead of print]

Garland CF, Gorham ED, Baggerly CA, Garland FC. Re: Prospective Study of Vitamin D and Cancer Mortality in the United States. *J Natl Cancer Inst.* June 4 2008;100:826-7.

Giovannucci E. Vitamin D status and cancer incidence and mortality. *Adv Exp Med Biol.* 2008;624:31-42.

Giovannucci E. Vitamin D and Cancer Incidence in the Harvard Cohorts. *Ann Epidemiol.* 2008 Feb 19; [Epub ahead of print]

Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer-A meta-analysis. *J Steroid Biochem Mol Biol.* 2008 Sep;111(3-5):195-9.

Goodwin WJ, Thomas GR, Parker DF, Joseph D, Levis S, Franzmann E, Anello C, Hu JJ. Unequal burden of head and neck cancer in the United States. *Head Neck.* 2008 Mar;30(3):358-71.

Grandin L, Orsi L, Troussard X, Monnereau A, Berthou C, Fenaux P, Marit G, Soubeyran P, Huguet F, Milpied N, Leporrier M, Hemon D, Clavel J. UV radiation exposure, skin type and lymphoid malignancies: results of a French case-control study. *Cancer Causes Control*. 2008;19 (3):305-315.

Grant WB. The effect of solar UVB doses and vitamin D production, skin cancer action spectra, and smoking in explaining links between skin cancers and solid tumours. *Eur J Cancer*. 2008;44:12-15.

Grant WB. Solar ultraviolet irradiance and cancer incidence and mortality. *Adv Exp Med Biol*. 2008;624:16-30.

Grant WB. Hypothesis-Ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. *Photochem Photobiol*. 2008;84:356-65. (3 ISI)

Grant WB. Response to comments by Norval and Woods to my hypothesis regarding vitamin D, viral infections and their sequelae. *Photochem Photobiol*. 2008 May-Jun;84(3):806-8.

Grant WB. An ecological study of cancer mortality rates including indices for dietary iron and zinc. *Anticancer Res*. 2008 May-Jun;28(3B):1955-63.

Grant WB. Re: Prospective Study of Vitamin D and Cancer Mortality in the United States. *JNCI* June 4 2008;100:826.

Grant WB. Ecologic approach is a powerful tool for cancer research. *Eur J Cancer Prev*. 2008 Aug;17(4):384.

Grant WB. Vitamin D, periodontal disease, tooth loss, and cancer risk. *Lancet Oncology*. 2008 July;9(7):612-613.

Grant WB. Commentary: Ecologic studies in identifying dietary risk factors for coronary heart disease and cancer. *Int J Epidemiol*. 2008 Aug 24. [Epub ahead of print]

Grant WB. Differences in vitamin D status may explain black-white differences in breast cancer survival rates. *J Natl Med Assoc*. 2008 Sept;100(9):1040.

Greenspan SL. Approach to the prostate cancer patient with bone disease. *J Clin Endocrinol Metab*. 2008 Jan;93(1):2-7.

Grimsrud TK, Andersen A. Protective effect from solar exposure, risk of an ecological fallacy. *Eur J Cancer*. 2008;44(1):16-18.

Heaney RP. Vitamin D and calcium interactions: functional outcomes. *Am J Clin Nutr*. 2008 Aug;88(2):541S-544S.

Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? *Adv Exp Med Biol*. 2008;624:1-15.

Hu DN, McCormick SA, Yu GP. Latitude and uveal melanoma. *Ophthalmology*. 2008 Apr;115(4):757; author reply 757-9.

Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS; Members of UKCAP Consortium. Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence. *Int J Cancer*. 2008 Aug 1;123(3):586-93.

Huh SY, Gordon CM. Vitamin D deficiency in children and adolescents: Epidemiology, impact and treatment. *Rev Endocr Metab Disord*. 2008 Jun;9(2):161-170.

Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin d intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. *Nutr Cancer*. 2008 Jul-Aug;60(4):421-41.

Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. *Curr Med Res Opin*. 2008;24:139-49.

Karami S, Brennan P, Hung RJ, Boffetta P, Toro J, Wilson RT, Zaridze D, Navratilova M, Chatterjee N, Mates D, Janout V, Kollarova H, Bencko V, Szeszenia-Dabrowska N, Holcatova I, Moukeria A, Welch R, Chanock S, Rothman N, Chow WH, Moore LE. Vitamin d receptor polymorphisms and renal cancer risk in central and eastern europe. *J Toxicol Environ Health A*. 2008 Jan;71(6):367-72.

Khazai N, Judd SE, Tangpricha V. Calcium and vitamin D: skeletal and extraskeletal health. *Curr Rheumatol Rep*. 2008 Apr;10(2):110-7.

Kricker A, Armstrong BK, Hughes AM, Goumas C, Smedby KE, Zheng T, Spinelli JJ, De Sanjose S, Hartge P, Melbye M, Willett EV, Becker N, Chiu BC, Cerhan JR, Maynadie M, Staines A, Cocco P, Boffeta P; for the Interlymph Consortium. Personal sun exposure and risk of non Hodgkin lymphoma: A pooled analysis from the Interlymph Consortium. *Int J Cancer*. 2008 Jan 1;122(1):144-54.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. *Am J Epidemiol*. 2008 Apr 15;167(8):925-34.

Kurihara N, Fan K, Thaler HT, Yang K, Lipkin M. Effect of a Western-Style Diet Fortified with Increased Calcium and Vitamin D on Mammary Gland of C57Bl/6 Mice. *J Med Food*. 2008 Jun;11(2):201-206.

Larriba MJ, Valle N, Alvarez S, Muñoz A. Vitamin D3 and colorectal cancer. *Adv Exp Med Biol*. 2008;617:271-80.

Larsson D, Hagberg M, Malek N, Kjellberg C, Senneberg E, Tahmasebifar N, Johansson V. Membrane initiated signaling by 1,25alpha-dihydroxyvitamin D3 in LNCaP prostate cancer cells. *Adv Exp Med Biol*. 2008;617:573-9.

Lu L, Qiu J, Liu S, Luo W. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. *Mol Cancer Ther*. 2008 May;7(5):1268-74.

Lucas RM, McMichael AJ, Armstrong BK, Smith WT. Estimating the global disease burden due to ultraviolet radiation exposure. *Int. J. Epidemiol*. 2008 37: 654-667.

McCullough ML, Bandera EV, Moore DF, Kushi LH. Vitamin D and calcium intake in relation to risk of endometrial cancer: A systematic review of the literature. *Prev Med*. 2008 Apr;46(4):298-302.

Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin d receptor expression in normal, premalignant, and malignant human lung tissue. *Cancer Epidemiol Biomarkers Prev*. 2008 May;17(5):1104-10.

Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. *Proc Natl Acad Sci U S A*. 2008 Jan 15;105(2):668-73. (7 ISI)

Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Could ultraviolet B irradiance and vitamin D be associated with lower incidence rates of lung cancer? *J Epidemiol Community Health*. 2008 Jan;62(1):69-74.

Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. *Breast J*. 2008;141:255-60.

Mucci LA, Spiegelman D. Vitamin D and prostate cancer risk—A less sunny outlook? *JNCI*. June 2008;100 (11):759-61.

Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer TM. The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells. *Clin Cancer Res*. 2008 Jun 1;14(11):3562-3570.

Neuhouser ML, Sorensen B, Hollis BW, Ambis A, Ulrich CM, McTiernan A, Bernstein L, Wayne S, Gilliland F, Baumgartner K, Baumgartner R, Ballard-Barbash R. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. *Am J Clin Nutr*. 2008 Jul;88(1):133-9.

Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. *J Clin Oncol*. 2008 Jun 20;26(18):2984-91.

Nittke T, Selig S, Kallay E, Cross HS. Nutritional calcium modulates colonic expression of vitamin D receptor and pregnane X receptor target genes. *Mol Nutr Food Res*. 2008 Jun;52 Suppl 1:S45-51.

- Norval M, Woods GM. Comment on "Hypothesis-Ultraviolet-B Irradiance and Vitamin D Reduce the Risk of Viral Infections and thus their Sequelae, Including Autoimmune Diseases and some Cancers" by W.B. Grant, Photochem. Photobiol. (2007). Photochem Photobiol. 2008 May-Jun;84(3):802-5.
- Nürnberg B, Schadendorf D, Gärtner B, Pföhler C, Herrmann W, Tilgen W, Reichrath J. Progression of malignant melanoma is associated with reduced 25-hydroxyvitamin D serum levels. *Exp Dermatol*. 2008 Jul;17(7):627.
- Obara W, Mizutani Y, Oyama C, Akaza H, Ishii N, Kohri K, Namiki M, Okuyama A, Shima H, Yokoyama M, Shuin T, Miki T, Watanabe Y, Fujioka T. Prospective study of combined treatment with interferon-alpha and active vitamin D for Japanese patients with metastatic renal cell carcinoma. *Int J Urol*. 2008 Jul 21. [Epub ahead of print]
- Oberyszyn TM. Non-melanoma skin cancer: Importance of gender, immunosuppressive status and vitamin D. *Cancer Lett*. 2008 Mar 18;261(2):127-36.
- Ochs-Balcom HM, Cicek MS, Thompson CL, Tucker TC, Elston RC, Plummer S, Casey G, Li L. Association of Vitamin D Receptor Gene Variants, Adiposity and Colon Cancer. *Carcinogenesis*. 2008 Sep;29(9):1788-93.
- Oh EY, Wood PA, Du-Quiton J, Hrushesky WJ. Seasonal modulation of post-resection breast cancer metastasis. *Breast Cancer Res Treat*. 2008 Sep;111(2):219-28.
- Overcash JA. Vitamin d in older patients with cancer. *Clin J Oncol Nurs*. 2008 Aug;12(4):655-62.
- Parisi E, Reñé JM, Cardús A, Valcheva P, Piñol-Felis C, Valdivielso JM, Fernández E. Vitamin D receptor levels in colorectal cancer Possible role of BsmI polymorphism. *J Steroid Biochem Mol Biol*. 2008 Jul;111(1-2):87-90.
- Peng X, Hawthorne M, Vaishnav A, St-Arnaud R, Mehta RG. 25-Hydroxyvitamin D(3) is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. *Breast Cancer Res Treat*. 2008 Jan 20; [Epub ahead of print]
- Pérez-López FR. Sunlight, the vitamin D endocrine system, and their relationships with gynaecologic cancer. *Maturitas*. 2008 Feb 20;59(2):101-13.
- Pilz S, Dobnig H, Winkhofer-Roob B, Riedmüller G, Fischer JE, Seelhorst U, Wellnitz B, Boehm BO, März W. Low Serum Levels of 25-Hydroxyvitamin D Predict Fatal Cancer in Patients Referred to Coronary Angiography. *Cancer Epidemiol Biomarkers Prev*. 2008 May;17(5):1228-33.
- Porojnicu AC, Dahlback A, Moan J. Sun exposure and cancer survival in Norway: changes in the risk of death with season of diagnosis and latitude. *Adv Exp Med Biol*. 2008;624:43-54.
- Reichrath J, Nürnberg B. Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs). *Adv Exp Med Biol*. 2008;624:203-14.
- Rohan TE et al. Low-Fat Dietary Pattern and Risk of Benign Proliferative Breast Disease: A Randomized, Controlled Dietary Modification Trial. *Cancer Prev Res* first published on August 18, 2008 as doi:10.1158/1940-6207.CAPR-08-0003
- Rossi M, McLaughlin JK, Laggiou P, Bosetti C, Talamini R, Lipworth L, Giacosa A, Montella M, Franceschi S, Negri E, La Vecchia C. Vitamin D intake and breast cancer risk: a case-control study in Italy. *Ann Oncol*. 2008 Aug 18. [Epub ahead of print]
- Rosso S, Sera F, Segnan N, Zanetti R. Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: Results from a long-term follow-up study of Italian patients. *Eur J Cancer*. 2008 June;44 (9):1275-1281.
- Schwartz GG. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. *Cancer Epidemiol Biomarkers Prev*. 2008 Mar;17(3):478-83.
- Schwartz GG. Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy. *Ann Epidemiol*. 2008 Jul 9. [Epub ahead of print]

- Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. 1alpha,25-Dihydroxyvitamin D(3) down-regulates expression of prostate specific membrane antigen in prostate cancer cells. *Prostate*. 2008 Feb 4;68(7):773-783
- Sinotte M, Rousseau F, Ayotte P, Dewailly E, Diorio C, Giguere Y, Berube S, Brisson J. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. *Endocr Relat Cancer*. 2008 Aug 21. [Epub ahead of print]
- Skinner HG. Vitamin D for the treatment and prevention of pancreatic cancer. *Cancer Biol Ther*. 2008 Apr 10;7(3).
- Soerjomataram I, Louwman WJ, Lemmens VE, Coebergh JW, de Vries E. Are Patients with Skin Cancer at Lower Risk of Developing Colorectal or Breast Cancer? *Am J Epidemiol*. 2008 167: 1421-1429.
- Stallings VA. Childhood cancer and vitamins: prevention and treatment. *Pediatr Blood Cancer*. 2008 Feb;50(2 Suppl):442-4; discussion 451.
- Stolzenberg-Solomon RZ. Vitamin D and Pancreatic Cancer. *Ann Epidemiol*. 2008 May 24. [Epub ahead of print]
- Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Barnettson RA, Porteous ME, Dunlop MG, Campbell H. Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a FokI variant supports a chemoprotective action of Vitamin D intake mediated through VDR binding. *Int J Cancer*. 2008 Aug 15. [Epub ahead of print]
- Thorne J, Campbell MJ. The vitamin D receptor in cancer. *Proc Nutr Soc*. 2008 May;67(2):115-27.
- Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ. VDR and SRD5A2 Polymorphisms Combine to Increase Risk for Prostate Cancer in Both Non-Hispanic White and Hispanic White Men. *Clin Cancer Res*. 2008 May 15;14(10):3223-3229.
- Ulrich CM, Holmes RS. Shedding light on colorectal cancer prognosis: vitamin d and beyond. *J Clin Oncol*. 2008 Jun 20;26(18):2937-9.
- Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with different types of cancer. *Acta Oncol*. 2008 Jul 4:1-11. [Epub ahead of print]
- Waltz P, Chodick G. Assessment of ecological regression in the study of colon, breast, ovary, non-Hodgkin's lymphoma, or prostate cancer and residential UV. *Eur J Cancer Prev*. 2008 Jun;17(3):279-86.
- Wang C, Baumgartner RN, Yang D, Slattery ML, Murtaugh MA, Byers T, Hines LM, Giuliano AR, Baumgartner KB. No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women. *Breast Cancer Res Treat*. 2008 Aug 1. [Epub ahead of print]
- Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of Vitamin D Deficiency in Breast Cancer Patients on Bisphosphonates. *Oncologist*. 2008 Jul;13(7):821-7.
- Weingarten M, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD003548.
- Wigle DT, Turner MC, Gomes J, Parent ME. Role of hormonal and other factors in human prostate cancer. *J Toxicol Environ Health B Crit Rev*. 2008 Mar;11(3-4):242-59.



(176 papers (28>2))

Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin d and calcium intake and premenopausal breast cancer risk in a german case-control study. *Nutr Cancer*. 2007;59(1):54-61.

Abnet CC, Chen W, Dawsey SM, Wei WQ, Roth MJ, Lie B, Lu N, Taylor PR, Qiao YL. Serum 25(OH)-vitamin D concentration and risk of esophageal squamous dysplasia. *Cancer Epidemiol Biomarkers Prev* 2007;16:1889-93.

Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. *BJU Int*. 2007 Oct;100(4):749-54.

Agic A, Xu H, Altgassen C, Noack F, Wolfler MM, Diedrich K, Friedrich M, Taylor RN, Hornung D. Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. *Reprod Sci*. 2007 Jul;14(5):486-97.

Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB; for the Prostate, Lung, Colorectal, and Ovarian Trial Project Team. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. *Cancer Epidemiol Biomarkers Prev*. 2007 Dec;16(12):2623-30.

Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of Vitamin D insensitive prostate cancer cells. *J Steroid Biochem Mol Biol*. 2007 Mar;103(3-5):712-6.

Ali MM, Vaidya V. Vitamin D and cancer. *J Cancer Res Ther*. 2007 Oct-Dec;3(4):225-30.

Almquist M, Manjer J, Bondeson L, Bondeson AG. Serum calcium and breast cancer risk: results from a prospective cohort study of 7,847 women. *Cancer Causes Control*. 2007 Aug;18(6):597-602.

Armstrong BK, Krickler A. Sun Exposure and Non-Hodgkin Lymphoma. *Cancer Epidemiol Biomarkers Prev*. 2007 16: 396-400.

Atkinson SA. Vitamin D status and bone biomarkers in childhood cancer. *Pediatr Blood Cancer*. 2007 Dec 6;50(S2):479-482.

Autier P, Gandini S. Vitamin D Supplementation and Total Mortality: A Meta-analysis of Randomized Controlled Trials. *Arch Intern Med*. 2007 Sep 10;167(16):1730-7. (2 ISI)

Aviner S, Dabby D, London D, Feinmesser M, Ash S, Steinberg R, Jakim I. Renal Cell Carcinoma in a Child Presented as Bilateral Femur Neck Fractures Caused by Severe Vitamin D Deficiency. *J Pediatr Hematol Oncol*. 2007 Dec;29(12):848-850.

Becker S, Cordes T, Diesing D, Diedrich K, Friedrich M. Expression of 25 hydroxyvitamin D3-1alpha-hydroxylase in human endometrial tissue. *J Steroid Biochem Mol Biol*. 2007 Mar;103(3-5):771-5.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. *J Clin Oncol*. 2007 Feb 20;25(6):669-74. (9 ISI)

Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. *Cancer Chemother Pharmacol*. 2007 Apr;59(5):581-7. (2 ISI)

Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabeesh NJ. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. *Mol Cancer Ther*. 2007 Apr;6(4):1433-9.

Bertone-Johnson ER. Prospective studies of dietary vitamin D and breast cancer: more questions raised than answered. *Nutr Rev*. 2007 Oct;65(10):459-66.

Bikle DD. What is new in vitamin D: 2006-2007. *Curr Opin Rheumatol*. 2007 Jul;19(4):383-8.

Bonjour JP, Chevalley T, Fardellone P. Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer. *Br J Nutr*. 2007 Apr;97(4):611-6. (1 GS)

- Bosetti C, Scotti L, Maso LD, Talamini R, Montella M, Negri E, Ramazzotti V, Franceschi S, Vecchia CL. Micronutrients and the risk of renal cell cancer: A case-control study from Italy. *Int J Cancer*. 2007 Feb 15;120(4):892-6.
- Braverman AS. Evidence that high calcium and vitamin D intake decrease the risk of breast cancer in premenopausal women: implications for breast cancer prevention and screening. *South Med J*. 2007 Nov;100(11):1061-2.
- Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin D. *Cancer Epidemiol Biomarkers Prev*. 2007 May;16(5):929-33.
- Brown DJ, Milroy R, Preston T, McMillan DC. The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. *J Clin Pathol*. 2007 Jun;60(6):705-8.
- Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. *Bioorg Med Chem*. 2007 Aug 1;15(15):5047-60.
- Byers S, Shah S. Vitamin D and the regulation of Wnt/beta-catenin signaling and innate immunity in colorectal cancer. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S118-20.
- Byrne B, Welsh J. Identification of novel mediators of Vitamin D signaling and 1,25(OH)₂D₃ resistance in mammary cells. *J Steroid Biochem Mol Biol*. 2007 Mar;103(3-5):703-7. (2 ISI)
- Byrne BM, Welsh J. Altered thioredoxin subcellular localization and redox status in MCF-7 cells following 1,25-dihydroxyvitamin D₃ treatment. *J Steroid Biochem Mol Biol*. 2005 Oct;97(1-2):57-64.
- Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D₃ on human B cell differentiation. *J Immunol*. 2007 Aug 1;179(3):1634-47.
- Chen W, Dawsey SM, Qiao YL, Mark SD, Dong ZW, Taylor PR, Zhao P, Abnet CC. Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. *Br J Cancer*. 2007 June 26;97:123-128.
- Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. *J Biol Chem*. 2007 Mar 23;282(12):8704-14.
- Cross HS. Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells: modification of expression by epigenetic mechanisms and dietary substances. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S108-12.
- Davis CD, Hartmuller V, Freedman DM, Hartge P, Picciano MF, Swanson CA, Milner JA. Vitamin D and cancer: current dilemmas and future needs. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S71-4.
- Davis CD, Dwyer JT. The "Sunshine Vitamin": Benefits Beyond Bone? *J Natl Cancer Inst*. 2007 Nov;99:1563-5.
- Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. *Nat Rev Cancer*. 2007 Sep;7(9):684-700. (15 ISI)
- de Vries E, Soerjomataram I, Houterman S, Louwman MW, Coebergh JW. Decreased risk of prostate cancer after skin cancer diagnosis: A protective role of ultraviolet radiation? *Am J Epidemiol*. 2007 165: 966-972. (2 GS)
- Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial. *Int J Cancer*. 2007 Dec 18;122(8):1690-1694.
- Dizdar O, Harputluoglu H, Altundag K. Vitamin d intake and breast cancer risk in postmenopausal women. *Arch Intern Med*. 2007 Dec 10;167(22):2532.
- Eelen G, Gysemans C, Verlinden L, Vanoirbeek E, De Clercq P, Van Haver D, Mathieu C, Bouillon R, Verstuyf A. Mechanism and Potential of the Growth-Inhibitory Actions of Vitamin D and Ana-logs. *Curr Med Chem*. 2007;14(17):1893-1910.

Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA. Lack of Association between Serum Levels of 25-Hydroxyvitamin D and the Subsequent Risk of Prostate Cancer in Finnish Men. *Cancer Epidemiol Biomarkers Prev*. 2007 Dec;16(12):2784-6.

Feldman D, Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S. Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S113-5.

Fischer D, Seifert M, Becker S, Ludders D, Cordes T, Reichrath J, Friedrich M. 25-Hydroxyvitamin D3 1 α -Hydroxylase Splice Variants in Breast Cell Lines MCF-7 and MCF-10. *Cancer Genomics Proteomics*. 2007 Jul-Aug;4(4):295-300.

Fleet JC. What have genomic and proteomic approaches told us about vitamin D and cancer? *Nutr Rev*. 2007 Aug;65(8 Pt 2):S127-30.

Flugge J, Krusekopf S, Goldammer M, Osswald E, Terhalle W, Malzahn U, Roots I. Vitamin D receptor haplotypes protect against development of colorectal cancer. *Eur J Clin Pharmacol*. 2007 Nov;63(11):997-1005

Fraser DR. Exploration of possible mechanisms linking vitamin D status and dietary calcium to prostate cancer. *Br J Nutr*. 2007 Apr;97(4):596-7.

Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. *JNCI*. 2007;99:1594-1602.

Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. *BMC Immunol*. 2007 Mar 30;8:5.

Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC. Vitamin D and prevention of breast cancer: Pooled analysis. *J Steroid Biochem Mol Biol*. 2007;103(3-5):708-11. (7 ISI, 10 GS)

Garland CF, Grant WB, Mohr SB, Gorham ED, Garland FC. What is the dose-response relationship between vitamin D and cancer risk? *Nutr Rev*. 2007 Aug;65(8 Pt 2):S91-5.

Gilchrest BA. Sun protection and Vitamin D: three dimensions of obfuscation. *J Steroid Biochem Mol Biol*. 2007 Mar;103(3-5):655-63. (2 ISI)

Giovannucci E. Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostate cancer risk. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S77-9.

Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. *J Bone Miner Res*. 2007 Dec;22 Suppl 2:V81-5.

Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF. Optimal vitamin d status for colorectal cancer prevention a quantitative meta analysis. *Am J Prev Med*. 2007 Mar;32(3):210-6. (29 ISI, 17 GS)

Grant WB. Vitamin D and cancer risk among American Indians. *Cancer Epidemiol Biomarkers Prev* 2007;16:183.

Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UV irradiance and smoking. *Int J Cancer*. 2007;120:1123-7. (6 ISI, 7 GS)
Note: I have a correction to this paper that I would be happy to supply. I should have done a multiple regression analysis. 15 cancers show evidence of a UVB effect, not 17 reported.

Grant WB. A meta-analysis of second cancers after a diagnosis of nonmelanoma skin cancer: additional evidence that solar ultraviolet-B irradiance reduces the risk of internal cancers. *J Steroid Biochem Mol Biol* 2007;103(3-5):668-674. (3 ISI)

Grant WB. Does Solar Ultraviolet Irradiation affect Cancer Mortality Rates in China? *Asian Pac J Cancer Prev*. 2007 Apr-Jun;8(2):236-42.

Grant WB. Roles of solar ultraviolet radiation and vitamin D in human health and how to obtain vitamin D. *Expert Rev Dermatol*. 2007;2(5):563-77.

Grant WB, Garland CF, Gorham ED. An estimate of cancer mortality rate reductions in Europe and the U.S. with 1000 I.U. of oral vitamin D per day. *Rec Results Cancer Res.* 2007;174:225-34.

Grant WB, Moan J, Reichrath J. Comment on "The effects on human health from stratospheric ozone depletion and its interactions with climate change" by M. Norval, A. P. Cullen, F. R. de Gruijl, J. Longstreth, Y. Takizawa, R. M. Lucas, F. P. Noonan and J. C. van der Leun, *Photochem. Photobiol. Sci.*, 2007, 6, 232. *Photochem Photobiol Sci.* 2007 Aug;6(8):912-5.

Grau MV, Baron JA, Sandler RS, Wallace K, Haile RW, Church TR, Beck GJ, Summers RW, Barry EL, Cole BF, Snover DC, Rothstein R, Mandel JS. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. *J Natl Cancer Inst.* 2007 Jan 17;99(2):129. (3 ISI)

Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. *Carcinogenesis.* 2007 Feb;28(2):390-7. (2 ISI)

Herring PA, Ingels J, Palmieri G, Hasty KA. 1alpha,25-Dihydroxyvitamin D(3) enhances proliferation of rat prostate cancer cells in the presence of living bone. *J Steroid Biochem Mol Biol.* 2007 Mar;103(3-5):737-41

Hewison M, Burke F, Evans KN, Lamas DA, Sansom DM, Liu P, Modlin RL, Adams JS. Extra-renal 25-hydroxyvitamin D(3)-1alpha-hydroxylase in human health and disease. *J Steroid Biochem Mol Biol.* 2007 Mar;103(3-5):316-21.

Holick MF. Vitamin D deficiency. *N Engl J Med.* 2007 Jul 19;357(3):266-81. Review. (4 GS)

Hosgood HD 3rd, Baris D, Zahm SH, Zheng T, Cross AJ. Diet and risk of multiple myeloma in Connecticut women. *Cancer Causes Control.* 2007 Dec;18(10):1065-76.

Hutchinson PE, Osborne JE. Do we need a revised public health policy on sun exposure? *British Journal of Dermatology.* 2007;156 (4), 786-788.

Ingles SA. Can diet and/or sunlight modify the relationship between vitamin D receptor polymorphisms and prostate cancer risk? *Nutr Rev.* 2007 Aug;65(8 Pt 2):S105-7.

Jacobs ET, Alberts DS, Benuzillo J, Hollis BW, Thompson PA, Martinez ME. Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. *J Steroid Biochem Mol* 2007;103(3-5): 752-756.

Jacobs ET, Thompson PA, Martinez ME. Diet, Gender, and Colorectal Neoplasia. *J Clin Gastroenterol.* 2007 Sep;41(8):731-746.

Jimenez-Lara AM. Colorectal cancer: Potential therapeutic benefits of Vitamin D. *Int J Biochem Cell Biol.* 2007;39(4):672-7.

John EM, Koo J, Schwartz GG. Sun Exposure and Prostate Cancer Risk: Evidence for a Protective Effect of Early-Life Exposure. *Cancer Epidemiol Biomarkers Prev* 2007;16 1283-1286.

John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Breast Cancer Risk in a Multiethnic Population. *Am J Epidemiol.* 2007 166: 1409-1419.

Kadiyska T, Yakulov T, Kaneva R, Nedin D, Alexandrova A, Gegova A, Savov A, Mitev V, Kremensky I. Vitamin D and estrogen receptor gene polymorphisms and the risk of colorectal cancer in Bulgaria. *Int J Colorectal Dis.* 2007 Apr;22(4):395-400.

Kinoshita S, Wagatsuma Y, Okada M. Geographical distribution for malignant neoplasm of the pancreas in relation to selected climatic factors in Japan. *Int J Health Geogr.* 2007; 6: 34.

<http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1971256&blobtype=pdf>

Knight JA, Lesosky M, Barnett H, Raboud JM, Vieth R. Vitamin D and Reduced Risk of Breast Cancer: A Population-Based Case-Control Study. *Cancer Epidemiol Biomarkers Prev* 2007;16: 422-429. (10 ISI, 1 GS)

- Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. *J Steroid Biochem Mol Biol*. 2007 Mar;103(3-5):694-702. (2 ISI)
- Krishnan AV, Swami S, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S121-3.
- Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. *J Bone Miner Res*. 2007 Dec;22 Suppl 2:V74-80.
- Kutuzova GD, Deluca HF. 1,25-Dihydroxyvitamin D(3) regulates genes responsible for detoxification in intestine. *Toxicol Appl Pharmacol*. 2007 Jan 1;218(1):37-44. (2 ISI)
- Lagunova Z, Porojnicu AC, Dahlback A, Berg JP, Beer TM, Moan J. Prostate cancer survival is dependent on season of diagnosis. *Prostate*. 2007 Sep 1;67(12):1362-70.
- Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr*. 2007 Jun;85(6):1586-91. (66 ISI, 40 GS)
- Lappe JM, Heaney RP. Reply to RP Ojha et al. *Am J Clin Nutr* 2007 86: 1805-1806.
- Larriba MJ, Valle N, Palmer HG, Ordonez-Moran P, Alvarez-Diaz S, Becker KF, Gamallo C, de Herreros AG, Gonzalez-Sancho JM, Munoz A. The inhibition of Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. *Endocr Relat Cancer*. 2007 Mar;14(1):141-51.
- Lechner D, Kállay E, Cross HS. 1alpha,25-dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells. *Mol Cell Endocrinol*. 2007 Jan 15;263(1-2):55-64.
- Lee SS, Crabb SJ, Janghra N, Carlberg C, Williams AC, Cutress RI, Packham G, Hague A. Subcellular localisation of BAG-1 and its regulation of vitamin D receptor-mediated transactivation and involucrin expression in oral keratinocytes: implications for oral carcinogenesis. *Exp Cell Res*. 2007 Sep 10;313(15):3222-38.
- Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. *J Invest Dermatol*. 2007 Feb;127(2):276-80. (2 ISI)
- Li H, Stampfer MJ, Hollis JBW, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Jing Ma J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. *PLoS Med*. 2007;4(3): e103. (3 ISI)
- Lin J, JoAnn E. Manson; I-Min Lee; Nancy R. Cook; Julie E. Buring; Shumin M. Zhang. Intakes of Calcium and Vitamin D and Breast Cancer Risk in Women. *Arch Intern Med*. 2007;167:1050-1059. (18 ISI)
- Lucas RM. Critically evaluating the evidence: risk versus benefit for sun exposure. *Expert Review of Dermatology*, October 2007;2:515-518.
- Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT. Vitamin d receptor gene polymorphisms and epithelial ovarian cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2007 Dec;16(12):2566-71.
- Matusiak D, Benya RV. CYP27A1 and CYP24 Expression as a Function of Malignant Transformation in the Colon. *J Histochem Cytochem*. 2007 Dec;55(12):1257-64.
- McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, Thun MJ, Calle EE. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. *Breast Cancer Res*. 2007;9(1):R9. (7 ISI)
- Mernitz H, Smith DE, Wood RJ, Russell RM, Wang XD. Inhibition of lung carcinogenesis by 1alpha,25-dihydroxyvitamin D(3) and 9-cis retinoic acid in the A/J mouse model: Evidence of retinoid mitigation of vitamin D toxicity. *Int J Cancer*. 2007 Apr 1;120(7):1402-9.

- Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. *Prostate*. 2007 Jun 15;67(9):911-23.
- Mittal RD, Manchanda PK, Bhat S, Bid HK. Association of vitamin-D receptor (Fok-I) gene polymorphism with bladder cancer in an Indian population. *BJU Int*. 2007 Apr;99(4):933-7.
- Moan J, Porojnicu A, Lagunova Z, Berg JP, Dahlback A. Colon cancer: Prognosis for different latitudes, age groups and seasons in Norway. *J Photochem Photobiol B: Biol*. 2007;89:148-55.
- Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Is ultraviolet B irradiance inversely associated with incidence rates of endometrial cancer: an ecological study of 107 countries. *Prev Med*. 2007 Nov;45(5):327-31.
- Mordan-McCombs S, Valrance M, Zinser G, Tenniswood M, Welsh J. Calcium, vitamin D and the vitamin D receptor: impact on prostate and breast cancer in preclinical models. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S131-3.
- Mullin GE, Dobs A. Vitamin D and its role in cancer and immunity: a prescription for sunlight. *Nutr Clin Pract*. 2007 Jun;22(3):305-22. (2 ISI, 1 GS)
- Murillo G, Matusiak D, Benya RV, Mehta RG. Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. *J Steroid Biochem Mol* 2007;103(3-5):763-767.
- Nasri H, Baradaran A. The influence of serum 25-hydroxy vitamin D levels on Helicobacter Pylori Infections in patients with end-stage renal failure on regular hemodialysis. *Saudi J Kidney Dis Transpl*. 2007 Jun;18(2):215-9.
- Nielsen LR, Mosekilde L. [Vitamin D and breast cancer] *Ugeskr Laeger*. 2007 Apr 2;169(14):1299-302. Review. Danish.
- Norsa A, Martino V. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. *Cancer Biother Radiopharm*. 2007 Feb;22(1):50-5.
- Norval M, de Gruijl FR. Reply to the "Comment on "The effects on human health from stratospheric ozone depletion and its interactions with climate change" by W. B. Grant, J. Moan and J. Reichrath, *Photochem. Photobiol. Sci.*, 2007, 6, DOI: 10.1039/b705482c. *Photochem Photobiol Sci*. 2007 Aug;6(8):916-8. (2 ISI)
- Obara W, Suzuki Y, Kato K, Tanji S, Konda R, Fujioka T. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. *Int J Urol*. 2007 Jun;14(6):483-7.
- Obara W, Konda R, Akasaka S, Nakamura S, Sugawara A, Fujioka T. Prognostic Significance of Vitamin D Receptor and Retinoid X Receptor Expression in Renal Cell Carcinoma. *J Urol*. 2007 Oct;178(4 Pt 1):1497-503.
- Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL. Calcium and Vitamin D Intakes in Relation to Risk of Distal Colorectal Adenoma in Women. *Am J Epidemiol*. 2007 165: 1178-1186. (2 ISI)
- Ojha RP, Felini MJ, Fischbach LA. Vitamin D for cancer prevention: valid assertion or premature anointment? *Am J Clin Nutr*. 2007; 85:1804-5.
- O'Keefe SJ, Chung D, Mahmoud N, Sepulveda AR, Manafe M, Arch J, Adada H, van der Merwe T. Why do African Americans get more colon cancer than Native Africans? *J Nutr*. 2007 Jan;137(1 Suppl):175S-182S. (3 ISI)
- Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. *Br J Cancer*. 2007 Jul 31;97(3):446-51.
- Ozbek U, Kandilci A, van Baal S, Bonten J, Boyd K, Franken P, Fodde R, Grosveld GC. SET-CAN, the product of the t(9;9) in acute undifferentiated leukemia, causes expansion of early hematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice. *Am J Pathol*. 2007 Aug;171(2):654-66.
- Park SY, Murphy SP, Wilkens LR, Nomura AM, Henderson BE, Kolonel LN. Calcium and Vitamin D Intake and Risk of Colorectal Cancer: The Multiethnic Cohort Study. *Am J Epidemiol*. 2007 165: 784-93. (10 ISI)

- Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN. Calcium, vitamin D, and dairy product intake and prostate cancer risk: The Multiethnic Cohort Study. *Am J Epidemiol*. 2007 Dec 1;166(11):1270-1279.
- Patino-Garcia B, Arroyo C, Rangel-Villalobos H, Soto-Vega E, Velarde-Felix JS, Gabilondo F, Sandoval-Ramirez L, Figuera LE. Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population. *Rev Invest Clin*. 2007 Jan-Feb;59(1):25-31.
- Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C, Berciano MT, Lafarga M, Munoz A. Vitamin D regulates the phenotype of human breast cancer cells. *Differentiation*. 2007 Mar;75(3):193-207. (8 ISI)
- Perez-Fernandez, R.; Seoane, S.; Garcia-Caballero, T.; Segura, C.; Macia, M. Vitamin D, Pit-1, GH, and PRL: Possible Roles in Breast Cancer Development. *Current Medicinal Chemistry*, 2007;14(29):3051-8.
- Peng X, Mehta RG. Differential expression of prohibitin is correlated with dual action of Vitamin D as a proliferative and antiproliferative hormone in breast epithelial cells. *J Steroid Biochem Mol Biol*. 2007 Mar;103(3-5):446-50.
- Petridou ET, Dikalioti SK, Skalkidou A, Andrie E, Dessypris N, Trichopoulos D; The Childhood Hematology-Oncology Group. Sun exposure, birth weight, and childhood lymphomas: a case control study in Greece. *Cancer Causes Control*. 2007 Nov;18(9):1031-1037.
- Porojnicu AC, Lagunova Z, Robsahm TE, Berg JP, Dahlback A, Moan J. Changes in risk of death from breast cancer with season and latitude: Sun exposure and breast cancer survival in Norway. *Breast Cancer Res Treat*. 2007 May;102(3):323-8. (2 ISI)
- Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J. Seasonal and geographical variations in lung cancer prognosis in Norway Does Vitamin D from the sun play a role? *Lung Cancer*. 2007 Mar;55(3):263-70. (2 ISI, 2 GS)
- Porojnicu A, Robsahm TE, Berg JP, Moan J. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: A possible role of sun-induced Vitamin D. *J Steroid Biochem Mol* 2007;103(3-5): 675-678. (8 ISI)
- Povey JE, Darakhshan F, Robertson K, Bisset Y, Mekky M, Rees J, Doherty V, Kavanagh G, Anderson N, Campbell H, MacKie RM, Melton DW. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. *Carcinogenesis*. 2007 May;28(5):1087-93.
- Purdue MP, Lan Q, Kricker A, Vajdic CM, Rothman N, Armstrong BK. Vitamin D receptor gene polymorphisms and risk of non-Hodgkin's lymphoma. *Haematologica*. 2007 Aug;92(8):1145-6.
- Purdue MP, Hartge P, Davis S, et al. Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. *Cancer Causes Control*. 2007 18(9):989-99
- Reichrath J, Lehmann B, Carlberg C, Varani J, Zouboulis CC. Vitamins as hormones. *Horm Metab Res*. 2007 Feb;39(2):71-84. Review. (3 ISI)
- Reichrath J. Vitamin D and the skin: an ancient friend, revisited. *Exp Dermatol*. 2007 Jul;16(7):618-25.
- Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, Seifert M. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. *Cancer Biol Ther*. 2007 Jan;6(1):48-55.
- Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. *Cancer Causes Control*. 2007 Sep;18(7):775-82. (1 ISI)
- Rohan T. Epidemiological studies of vitamin D and breast cancer. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S80-3.
- Rukin NJ, Luscombe C, Moon S, Bodiwala D, Liu S, Saxby MF, Fryer AA, Aldersea J, Hoban PR, Strange RC. Prostate cancer susceptibility is mediated by interactions between exposure to ultraviolet radiation and polymorphisms in the 5' haplotype block of the vitamin D receptor gene. *Cancer Lett*. 2007 Mar 18;247(2):328-335. (5 ISI, 3 GS)

Rukin NJ, Zeegers MP, Ramachandran S, Luscombe CJ, Liu S, Saxby M, Lear J, Strange RC. A comparison of sunlight exposure in men with prostate cancer and basal cell carcinoma. *Br J Cancer*. 2007 Feb 12;96(3):523-528.

Rukin NJ, Strange RC. What are the frequency, distribution, and functional effects of vitamin D receptor polymorphisms as related to cancer risk? *Nutr Rev*. 2007 Aug;65(8 Pt 2):S96-101. (3 ISI)

Rukin N, Blagojevic M, Luscombe CJ, Liu S, Saxby MF, Ramachandran S, Fryer AA, Jones PW, Strange RC. Associations between timing of exposure to ultraviolet radiation, T-stage and survival in prostate cancer. *Cancer Detect Prev*. 2007;31(6):443-9

Ryan-Harshman M, Aldoori W. Diet and colorectal cancer: Review of the evidence. *Can Fam Physician*. 2007 Nov;53(11):1913-20.

Santonocito, C., R. Capizzi, P. Concolino, M.M. Lavieri, A. Paradisi, S. Gentileschi, E. Torti, S. Rutella, S. Rocchetti, A. Di Carlo, E. Di Stasio, F. Ameglio, C. Zuppi, E. Capoluongo. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor Bsm1 polymorphism. *Br J Dermatol*. 2007;156:277.

Santos Arrontes D, Garcia Gonzalez JI, Martin Munoz MP, Castro Pita M, Manas Pelillo A, Paniagua Andres P. [Will the climate change affect the mortality from prostate cancer?] *Arch Esp Urol*. 2007 Mar;60(2):119-23. Spanish.

Schumann SA, Ewigman B. Double-dose vitamin D lowers cancer risk in women over 55. *J Fam Pract*. 2007 Nov;56(11):907-910.

Schwalfenberg G. Not enough vitamin D: health consequences for Canadians. *Can Fam Physician*. 2007 May;53(5):841-54. Review.

Schwartz GG. The 'Cocaine Blues' and Other Problems in Epidemiologic Studies of Vitamin D and Cancer. *Nutr Cancer*. 2007;65(8):S75-S76.

Schwartz GG, Skinner HG. Vitamin D status and cancer: new insights. *Curr Opin Clin Nutr Metab Care*. 2007 Jan;10(1):6-11. (14 ISI, 4 GS)

Schwartz GG, Porta M. Vitamin D, ecologic studies and endometrial cancer. *Prev Med*. 2007 Nov;45(5):323-4.

Seubwai W, Wongkham C, Puapairoj A, Khuntikeo N, Wongkham S. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. *Cancer*. 2007 Jun 15;109(12):2497-505.

Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. *Nat Immunol*. 2007 Mar;8(3):285-293.

Sinclair C. Vitamin D--an emerging issue in skin cancer control. Implications for public health practice based on the Australian experience. *Recent Results Cancer Res*. 2007;174:197-204. Review.

Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD. IL6 genotypes and colon and rectal cancer. *Cancer Causes Control*. 2007 Dec;18(10):1095-105.

Slattery ML. Vitamin D receptor gene (VDR) associations with cancer. *Nutr Rev*. 2007 Aug;65(8 Pt 2):S102-4.

Slattery ML, Herrick J, Wolff RK, Caan BJ, Potter JD, Sweeney C. CDX2 VDR Polymorphism and Colorectal Cancer. *Cancer Epidemiol Biomarkers Prev*. 2007 Dec;16(12):2752-5.

Soni LK, Hou L, Gapstur SM, Evens AM, Weisenburger DD, Chiu BC. Sun exposure and non-Hodgkin lymphoma: A population-based, case-control study. *Eur J Cancer*. 2007 Nov;43(16):2388-95.

Spina CS, Ton L, Yao M, Maehr H, Wolfe MM, Uskokovic M, Adorini L, M.F. Holick MF. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. *J Steroid Biochem Mol* 2007;103(3-5): 757-762.

Stallings VA. Childhood cancer and vitamins: Prevention and treatment. *Pediatr Blood Cancer*. 2007 Dec 6;50(S2):442-444.

- Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. *Mol Cancer Ther*. 2007 Jan;6(1):309-17.
- Tan J, Dwivedi PP, Anderson P, Nutchey BK, O'Loughlin P, Morris HA, May BK, Ferrante A, Hii CS. Antineoplastic agents target the 25-hydroxyvitamin D3 24-hydroxylase messenger RNA for degradation: implications in anticancer activity. *Mol Cancer Ther*. 2007 Dec;6(12):3131-8.
- Tezal M, DDS, PhD; Maureen A. Sullivan, DDS; Mary E. Reid, PhD; James R. Marshall, PhD; Andrew Hyland, PhD; Thom Loree, MD; Cheryl Lillis, BS; Linda Hauck, BA; Jean Wactawski-Wende, PhD; Frank A. Scannapieco, DMD, PhD. Chronic Periodontitis and the Risk of Tongue Cancer. *Arch Otolaryngol Head Neck Surg*. 2007;133:450-454.
- Timonen T, Näyhä S, Koskela T, Pukkala E. Are sunlight deprivation and influenza epidemics associated with the onset of acute leukemia? *Haematologica*. 2007 Nov;92(11):1553-6.
- Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased Expression of Corepressors in Aggressive Androgen-Independent Prostate Cancer Cells Results in Loss of 1{alpha},25-Dihydroxyvitamin D3 Responsiveness. *Mol Cancer Res*. 2007 Sep;5(9):967-80.
- Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Humphrey MC, Ostrander EA. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case control study of Caucasian and African-American women. *Breast Cancer Res*. 2007 Dec 7;9(6):R84.
- Tseng M, Byrne C, Evers KA, Daly MB. Dietary intake and breast density in high-risk women: a cross-sectional study. *Breast Cancer Res*. 2007 Oct 19;9(5):R72.
- Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J, Hakama M. Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16 302-307. (2 GS)
- Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K, Tracey E, Weiderpass E, Kliewer EV, Pompe-Kirn V, McBride ML, Martos C, Chia KS, Tonita JM, Jonasson JG, Boffetta P, Brennan P. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation. *Eur J Cancer*. 2007 May 29;43:1701-1712. (2 ISI, 1 GS)
- TwoRoger SS, I-Min Lee, Julie E. Buring, Bernard Rosner, Bruce W. Hollis, and Susan E. Hankinson. Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Incident Ovarian Cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16: 783-788. (2 ISI)
- Valrance ME, Brunet AH, Welsh J. VDR Dependent Inhibition of Mammary Tumor Growth by EB1089 and UV Radiation in vivo. *Endocrinology*. 2007 Oct;148(10):4887-94.
- Van Renterghem D. Lung cancer survival: vitamin d could be just a marker of physical fitness. *J Clin Oncol*. 2007 Dec 1;25(34):5537-8.
- van der Rhee HJ, de Vries E, Coebergh JW. [Favourable and unfavourable effects of exposure to sunlight] *Ned Tijdschr Geneesk*. 2007 Jan 13;151(2):118-22. Review. Dutch.
- Vollmer RT. Solar elastosis in cutaneous melanoma. *Am J Clin Pathol*. 2007 Aug;128(2):260-4.
- Wang JH, Tuohimaa P. Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human prostate cancer cells. *J Steroid Biochem Mol Biol*. 2007 Oct;107(1-2):100-5.
- Wang X, Wang TT, White JH, Studzinski GP. Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D(3) and is required for optimal cell differentiation. *Exp Cell Res*. 2007 Aug 15;313(14):3034-45.
- Weihkopf T, Becker N, Nieters A, Mester B, Deeg E, Elsner G, Blettner M, Seidler A. Sun exposure and malignant lymphoma: A population-based case-control study in Germany. *Int J Cancer*. 2007 Feb 20;120(11):2445-2451.

Welsh J. Vitamin D and prevention of breast cancer. *Acta Pharmacol Sin.* 2007 Sep;28(9):1373-82.

Wedren S, Magnusson C, Humphreys K, Melhus H, Kindmark A, Stiger F, Branting M, Persson I, Baron J, Weiderpass E. Associations between Androgen and Vitamin D Receptor Microsatellites and Postmenopausal Breast Cancer. *Cancer Epidemiol Biomarkers Prev.* 2007 Sep;16(9):1775-83.

Weigel NL. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. *Nutr Rev.* 2007 Aug;65(8 Pt 2):S116-7.

Welsh J. Targets of vitamin D receptor signaling in the mammary gland. *J Bone Miner Res.* 2007 Dec;22 Suppl 2:V86-90.

Wu FS, Zheng SS, Wu LJ, Teng LS, Ma ZM, Zhao WH, Wu W. Calcitriol inhibits the growth of MHCC97 hepatocellular cell lines by down-modulating c-met and ERK expressions. *Liver Int.* 2007 Jun;27(5):700-7.

Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL. A Nested Case-Control Study of Plasma 25-Hydroxyvitamin D Concentrations and Risk of Colorectal Cancer. *J Natl Cancer Inst.* 2007 July; 99: 1120-1129.

Yang K, Lipkin M, Newmark H, Rigas B, Daroqui C, Maier S, Augenlicht L. Molecular targets of calcium and vitamin D in mouse genetic models of intestinal cancer. *Nutr Rev.* 2007 Aug;65(8 Pt 2):S134-7.

Yaylim-Eraltan I, Arzu Ergen H, Arikan S, Okay E, Ozturk O, Bayrak S, Isbir T. Investigation of the VDR gene polymorphisms association with susceptibility to colorectal cancer. *Cell Biochem Funct.* 2007 Jan 23;25(6):731-737.

Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP Sr, Qin Q, Kilfoy B, Han J, Zheng T. Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. *Am J Epidemiol.* 2007 Jun 1;165(11):1255-64.

Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, Christiani DC. Circulating 25-hydroxyvitamin d levels predict survival in early-stage non-small-cell lung cancer patients. *J Clin Oncol.* 2007 Feb 10;25(5):479-85.



(111 papers, 45≥5)

Abedin SA, Banwell CM, Colston KW, Carlberg C, Campbell MJ. Epigenetic corruption of VDR signalling in malignancy. *Anticancer Res.* 2006 Jul-Aug;26(4A):2557-66.

Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. *Cancer Chemother Pharmacol.* 2006 Jan;57(2):234-40. (7 ISI)

Andersson P, Varenhorst E, Soderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. *Eur J Cancer.* 2006 Nov;42(16):2833-7.

Armstrong BK. Commentary: seeing the light. *Int J Epidemiol.* 2006 Apr;35(2):231-2.

Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, Stewart PM, O'Neill LP, Turner BM, Colston KW, Campbell MJ. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. *Clin Cancer Res.* 2006 Apr 1;12(7 Pt 1):2004-13. (17 ISI)

Bao BY, Yeh SD, Lee YF. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. *Carcinogenesis.* 2006 Jan;27(1):32-42. (8 ISI, 3 GS)

Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. *Carcinogenesis.* 2006 Sep;27(9):1883-93.

Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. *Anticancer Res.* 2006 Jul-Aug;26(4A):2647-51. (7 ISI)

- Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. *J Urol*. 2006 May;175(5):1613-23. (1 ISI, 3 GS)
- Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr*. 2006 Jul;84(1):18-28. (33 ISI, 38 GS)
- Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2000. *BMC Cancer*. 2006;6:264. (10 November 2006) (5 ISI, 6 GS)
- Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. *J Steroid Biochem Mol Biol*. 2006 Dec;102(1-5):156-62. (19 ISI)
- Campbell MJ, Adorini L. The vitamin D receptor as a therapeutic target. *Expert Opin Ther Targets*. 2006 Oct;10(5):735-48.
- Chang ET, Balter KM, Torrang A, Smedby KE, Melbye M, Sundstrom C, Glimelius B, Adami HO. Nutrient intake and risk of non-Hodgkin's lymphoma. *Am J Epidemiol*. 2006 Dec 15;164(12):1222-32.
- Christakos S, Dhawan P, Shen Q, Peng X, Benn B, Zhong Y. New insights into the mechanisms involved in the pleiotropic actions of 1,25dihydroxyvitamin D3. *Ann N Y Acad Sci*. 2006 Apr;1068:194-203. (3 ISI)
- Cicek MS, Liu X, Schumacher FR, Casey G, Witte JS. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2006 Dec;15(12):2549-52.
- Colli JL, Colli A. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. *Urol Oncol*. 2006 May-Jun;24(3):184-94. (1 ISI)
- Colston KW, Lowe LC, Mansi JL, Campbell MJ. Vitamin D status and breast cancer risk. *Anticancer Res*. 2006 Jul-Aug;26(4A):2573-80. (1 ISI)
- Cross HS. Commentary: from epidemiology to molecular biology—vitamin D and colorectal cancer prevention. *Int J Epidemiol*. 2006 Apr;35(2):225-7. (2 ISI, 5 GS)
- Cui Y, Rohan TE. Vitamin D, Calcium, and Breast Cancer Risk: A Review. *Cancer Epidemiol Biomarkers Prev* 2006 15: 1427-1437. (18 ISI)
- de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Goes JC, Figueira MA. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. *J Steroid Biochem Mol Biol*. 2006 Aug;100(4-5):184-92.
- Diesing D, Cordes T, Fischer D, Diedrich K, Friedrich M. Vitamin D—metabolism in the human breast cancer cell line MCF-7. *Anticancer Res*. 2006 Jul-Aug;26(4A):2755-9.
- Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Pollak M, Brisson J. Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. *Cancer Res*. 2006 Jan 1;66(1):588-97. (5 ISI)
- Egan KM. Commentary: sunlight, vitamin D, and the cancer connection revisited. *Int J Epidemiol*. 2006 Apr;35(2):227-30. (2 ISI, 6 GS)
- Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF, Chen TC. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. *Anticancer Res*. 2006 Jul-Aug;26(4A):2567-72. (1 ISI)
- Friedrich M, Diesing D, Cordes T, Fischer D, Becker S, Chen TC, Flanagan JN, Tangpricha V, Gherson I, Holick MF, Reichrath J. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. *Anticancer Res*. 2006 Jul-Aug;26(4A):2615-20.
- Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF. The role of vitamin D in cancer prevention. *Am J Public Health*. 2006 Feb;96(2):252-61. (90 ISI; 67 GS)

- Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? *Int J Epidemiol*. 2006 Apr;35(2):217-20. (8 ISI)
- Garland CF, Mohr SB, Gorham ED, Grant WB, Garland FC. Role of ultraviolet-B irradiance and vitamin D in the prevention of ovarian cancer. *Am J Prev Med*. 2006 Dec;31(6):512-4.
- Gilad LA, Tirosh O, Schwartz B. Phytoestrogens regulate transcription and translation of vitamin D receptor in colon cancer cells. *J Endocrinol*. 2006 Nov;191(2):387-98.
- Giovannucci E. The epidemiology of vitamin D and colorectal cancer: recent findings. *Curr Opin Gastroenterol*. 2006 Jan;22(1):24-9. (23 ISI, 18 GS)
- Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2006 Feb;15(2):203-10. (10 ISI)
- Giovannucci E. Commentary: vitamin D and colorectal cancer—twenty-five years later. *Int J Epidemiol*. 2006 Apr;35(2):222-4. (2 ISI)
- Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WH. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. *JNCI* 2006; 98:451-9. (110 ISI, 56 GS)
- Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and vitamin D in black and white male health professionals. *Cancer Epidemiol Biomarkers Prev*. 2006 Dec;15(12):2467-72.
- Gombart AF, Luong QT, Koeffler HP. Vitamin D compounds: activity against microbes and cancer. *Anticancer Res*. 2006 Jul-Aug;26(4A):2531-42.
- Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG, Munoz A. Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. *Anticancer Res*. 2006 Jul-Aug;26(4A):2669-81. Review. (1 ISI)
- Grant WB. Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. *J Natl Med Assoc*. 2006 Mar;98(3):357-64. (9 ISI, 4 GS)
- Grant WB. The likely role of vitamin D from solar ultraviolet-B irradiance in increasing cancer survival. *Anticancer Res*. 2006 Jul-Aug;26(4A):2605-14. (12 ISI)
- Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. *Prog Biophys Mol Biol*. 2006 Sep;92(1):65-79. (11 ISI, 18 GS)
- Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. *Anticancer Res*. 2006 Jul-Aug;26(4A):2687-99. (46 ISI, 23 GS)
- Grant WB, Gorham ED. Commentary: time for public health action on vitamin D for cancer risk reduction. *Int J Epidemiol*. 2006 Apr;35(2):224-5. (5 ISI, 5 GS)
- Grimes DS. Are statins analogues of vitamin D? *Lancet*. 2006 Jul 1;368(9529):83-6. (9 ISI)
- Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W, Severson RK, Davis S. Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). *Cancer Causes Control*. 2006 Oct;17(8):1045-52. (8 ISI)
- Holick MF. Calcium plus vitamin D and the risk of colorectal cancer. *N Engl J Med*. 2006 May 25;354(21):2287-8; author reply 2287-8. (3 ISI)
- Holick MF. High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc*. 2006 Mar;81(3):353-73. (39 ISI, 52 GS)
- Holick MF. Vitamin D: its role in cancer prevention and treatment. *Prog Biophys Mol Biol*. 2006 Sep;92(1):49-59. 27 ISI)

- Hollender A, Bjoro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H. Vitamin D deficiency in patients operated on for gastric lymphoma. *Scand J Gastroenterol*. 2006 Jun;41(6):673-81.
- Holt PR, Bresalier RS, Ma CK, Liu KF, Lipkin M, Byrd JC, Yang K. Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa. *Cancer*. 2006 Jan 15;106(2):287-96.
- Houghton LA, Vieth R. The case against ergocalciferol (vitamin D₂) as a vitamin supplement. *Am J Clin Nutr*. 2006;84:694-7.
- Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. *Int J Cancer*. 2006 Oct 15;119(8):1902-7.
- Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. *Anticancer Res*. 2006 Jul-Aug;26(4A):2543-9. (3 ISI)
- Kemmis CM, Salvador SM, Smith KM, Welsh J. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. *J Nutr*. 2006 Apr;136(4):887-92. (9 ISI)
- Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstrom G, Hellman P. 25-hydroxyvitamin D₃ 1 α -hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. *J Histochem Cytochem*. 2006 Mar;54(3):355-61.
- Klassen AC, Platz EA. What can geography tell us about prostate cancer? *Am J Prev Med*. 2006 Feb;30(2 Suppl):S7-15. (2 GS)
- Kommagani R, Caserta TM, Kadakia MP. Identification of vitamin D receptor as a target of p63. *Oncogene*. 2006 Jun 22;25(26):3745-51. (6 ISI)
- Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D₃ inhibition of adipogenesis in 3T3-L1 cells. *Am J Physiol Endocrinol Metab*. 2006 May;290(5):E916-24.
- Koren R, Wacksberg S, Weitsman GE, Ravid A. Calcitriol sensitizes colon cancer cells to H₂O₂-induced cytotoxicity while inhibiting caspase activation. *J Steroid Biochem Mol Biol*. 2006 Oct;101(2-3):151-60.
- Krause R, Matulla-Nolte B, Essers M, Brown A, Hopfenmuller W. UV radiation and cancer prevention: what is the evidence? *Anticancer Res*. 2006 Jul-Aug;26(4A):2723-7. (1 ISI)
- Kricker A, Armstrong B. Does sunlight have a beneficial influence on certain cancers? *Prog Biophys Mol Biol*. 2006 Sep;92(1):132-9. (5 ISI)
- Lambert JR, Kelly JA, Shim M, Huffer WE, Nordeen SK, Baek SJ, Eling TE, Lucia MS. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. *J Cell Physiol*. 2006 Sep;208(3):566-74. (4 ISI)
- Lechner D, Bajna E, Adlercreutz H, Cross HS. Genistein and 17 β -estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells. *Anticancer Res*. 2006 Jul-Aug;26(4A):2597-603. (3 ISI)
- Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Moller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. *Int J Cancer*. 2006;119:1530-36. (12 ISI)
- Lipkin M, Lamprecht SA. Mechanisms of action of vitamin D: recent findings and new questions. *J Med Food*. 2006 Summer;9(2):135-7.
- Lips P. Vitamin D physiology. *Prog Biophys Mol Biol*. 2006 Sep;92(1):4-8. (17 GS)
- Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T. Expression of vitamin D₃ receptor in kidney tumors. *Hum Pathol*. 2006 Oct;37(10):1268-78.
- Lucas RM, Repacholi MH, McMichael AJ. Is the current public health message on UV exposure correct? *Bull World Health Organ*. 2006 Jun;84(6):485-91. (6 ISI)

Maggi M, Crescioli C, Morelli A, Colli E, Adorini L. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). *J Endocrinol Invest.* 2006 Jul-Aug;29(7):665-74. (3 ISI)

Maruyama R, Aoki F, Toyota M, Sasaki Y, Akashi H, Mita H, Suzuki H, Akino K, Ohe-Toyota M, Maruyama Y, Tatsumi H, Imai K, Shinomura Y, Tokino T. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. *Cancer Res.* 2006 May 1;66(9):4574-83. (6 ISI)

Michaud DS. Vitamin d and pancreatic cancer risk in the alpha-tocopherol, Beta-carotene cancer prevention cohort. *Cancer Res.* 2006 Oct 15;66(20):9802-3.

Mohr SB, Gorham ED, Garland CF, Grant WB, Garland FC. Are low ultraviolet B and high animal protein intake associated with risk of renal cancer? *Int J Cancer.* 2006 Dec 1;119(11):2705-9.

Moon S, Holley S, Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC. Associations between G/A1229, A/G3944, T/C30875, C/T48200 and C/T65013 genotypes and haplotypes in the vitamin D receptor gene, ultraviolet radiation and susceptibility to prostate cancer. *Ann Hum Genet.* 2006 Mar;70(Pt 2):226-36. (10 ISI, 5 GS)

Moreno J, Krishnan AV, Peehl DM, Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. *Anticancer Res.* 2006 Jul-Aug;26(4A):2525-30.

Muller K, Schinn M, Reichrath J, Meineke V. 1alpha,25-Dihydroxyvitamin D3 modulates the response of human keratinocytes to ionizing radiation exposure. *Anticancer Res.* 2006 Jul-Aug;26(4A):2735-41.

Murtaugh MA, Sweeney C, Ma KN, Potter JD, Caan BJ, Wolff RK, Slattery ML. Vitamin d receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. *Nutr Cancer.* 2006;55(1):35-43.

Newman LA, Griffith KA, Jatoti I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. *J Clin Oncol.* 2006 Mar 20;24(9):1342-9. (14 ISI)

Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. *Cancer Res.* 2006 Apr 15;66(8):4516-24. (6 ISI)

Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. *Endocrinology.* 2006 Dec;147(12):5542-8. (10 ISI)

Palmieri C, MacGregor T, Girgis S, Vigushin D. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. *J Clin Pathol.* 2006 Dec;59(12):1334-6.

Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, Chuang SS, Nichols M, El-Hefnawy T, Hershberger PA. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. *Int J Cancer.* 2006 Oct 15;119(8):1819-28.

Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. *BMC Cancer.* 2006 Mar 16;6:68. (10 ISI)

Pena C, Garcia JM, Garcia V, Silva J, Dominguez G, Rodriguez R, Maximiano C, Garcia de Herreros A, Munoz A, Bonilla F. The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. *Int J Cancer.* 2006 Nov 1;119(9):2098-104. (5 ISI)

Peng X, Mehta R, Wang S, Chellappan S, Mehta RG. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. *Cancer Res.* 2006 Jul 15;66(14):7361-9.

Peterlik M, Cross HS. Dysfunction of the vitamin D endocrine system as common cause for multiple malignant and other chronic diseases. *Anticancer Res.* 2006 Jul-Aug;26(4A):2581-8. Review.

Plant AS, Tisman G. Frequency of combined deficiencies of vitamin D and holotranscobalamin in cancer patients. *Nutr Cancer*. 2006;56(2):143-8.

Polesel J, Talamini R, Montella M, Parpinel M, Dal Maso L, Crispo A, Crovatto M, Spina M, La Vecchia C, Franceschi S. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. *Ann Oncol*. 2006 Apr;17(4):713-8. (8 ISI)

Reichrath J. The challenge resulting from positive and negative effects of sunlight: how much solar UV exposure is appropriate to balance between risks of vitamin D deficiency and skin cancer? *Prog Biophys Mol Biol*. 2006 Sep;92(1):9-16. (12 ISI, 7 GS)

Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. *Nucleic Acids Res*. 2006 Jan 24;34(2):543-54. (18 ISI)

Schwartz GG, Hanchette CL. UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States). *Cancer Causes Control*. 2006 Oct;17(8):1091-101. (6 ISI)

Sepulveda VA, Weigel NL, Falzon M. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. *Steroids*. 2006 Feb;71(2):102-15.

Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, Zinser G, Valrance M, Aranda A, Moras D, Norman A, Welsh J, Byers SW. The molecular basis of vitamin D receptor and beta-catenin crossregulation. *Mol Cell*. 2006 Mar 17;21(6):799-809.

Sieg J, Sieg A, Dreyhaupt J, Schmidt-Gayk H. Insufficient vitamin D supply as a possible co-factor in colorectal carcinogenesis. *Anticancer Res*. 2006 Jul-Aug;26(4A):2729-33. (1 ISI)

Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and the risk of pancreatic cancer in two cohort studies. *Cancer Epidemiol Biomarkers Prevention*. 2006 Sept.; 15(9):1688-1695. (21 ISI, 8 GS)

Slaterry ML, Sweeney C, Murtaugh M, Ma KN, Caan BJ, Potter JD, Wolff R. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. *Int J Cancer*. 2006 Jun 15;118(12):3140-6. (12 ISI)

Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H, Holick MF. Vitamin D and cancer. *Anticancer Res*. 2006 Jul-Aug;26(4A):2515-24. (5 ISI)

Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, Albanes D. A prospective nested case-control study of vitamin d status and pancreatic cancer risk in male smokers. *Cancer Res*. 2006 Oct 15;66(20):10213-9. (12 ISI, 6 GS)

Sweeney C, Curtin K, Murtaugh MA, Caan BJ, Potter JD, Slaterry ML. Haplotype analysis of common vitamin D receptor variants and colon and rectal cancers. *Cancer Epidemiol Biomarkers Prev*. 2006 Apr;15(4):744-9. (4 ISI)

Tavani A, Bosetti C, Franceschi S, Talamini R, Negri E, La Vecchia C. Occupational exposure to ultraviolet radiation and risk of non-Hodgkin lymphoma. *Eur J Cancer Prev*. 2006 Oct;15(5):453-457.

Tokar EJ, Ancrile BB, Ablin RJ, Webber MM. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer. *J Exp Ther Oncol*. 2006;5(4):323-33.

Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. *Cancer*. 2006 May 15;106(10):2136-42. (11 ISI)

Van der Rhee HJ, de Vries E, Coebergh JW. Does sunlight prevent cancer? A systematic review. *Eur J Cancer*. 2006 Sep;42(14):2222-32. (3 ISI, 4 GS)

Veronique-Baudin J, Dieye M, Kouyoumdjian JC, Vacheron F, Draganescu C, Azaloux H. [Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-alpha-reductase in a population of Afro-Caribbean population with prostate cancer] *Prog Urol*. 2006 Jun;16(3):303-10. French.

Vieth R, Choo R, Deboer L, Danjoux C, Morton G, Klotz L. Rise in Prostate-Specific Antigen in Men with Untreated Low-Grade Prostate Cancer Is Slower During Spring-Summer. *Am J Ther*. 2006 September/October;13(5):394-399.

Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N Engl J Med* 2006;354:684-96. (89 ISI, 69 GS)

Walsh J. Calcium and vitamin D. Ch. 31 in *Nutritional Oncology*, Second Edit., Heber D, Blackburn GL, Go VLW, Milner J (eds.). Academic Press, San Diego, CA. 2006:545-58.

Wolpowitz D, Gilchrist BA. The vitamin D questions: how much do you need and how should you get it? *J Am Acad Dermatol*. 2006 Feb;54(2):301-17. (17 ISI, 24 GS)

Yee SW, Campbell MJ, Simons C. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. *J Steroid Biochem Mol Biol*. 2006 Mar;98(4-5):228-35. (4 ISI)

Yu GP, Hu DN, McCormick SA. Latitude and Incidence of Ocular Melanoma. *Photochem Photobiol*. 2006;82:1621-6.

Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. *Curr Cancer Drug Targets*. 2006 May;6(3):229-44.

Zhang Y, Zhang J, Studzinski GP. AKT pathway is activated by 1, 25-dihydroxyvitamin D3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. *Cell Cycle*. 2006 Feb;5(4):447-51. (6 ISI)

Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Polymorphisms of vitamin d receptor and survival in early-stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev*. 2006 Nov;15(11):2239-45.



(6+ citat) (73 papers, 31 \geq 13)

Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, Yamada S, Makishima M. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. *J Lipid Res*. 2005 Jan;46(1):46-57. (16 ISI)

Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. *J Natl Med Assoc*. 2005 Nov;97(11):1471-8.

Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. *Cancer Epidemiol Biomarkers Prev*. 2005 Mar;14(3):586-9. (14 ISI)

Beer TM, Myrthue A, Eilers KM. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. *World J Urol*. 2005 Feb;23(1):28-32. (9 ISI, 5 GS)

Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. *Mutat Res*. 2005 Jan;589(1):47-65. (21 ISI)

Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2005 Aug;14(8):1991-7. (22 ISI, 20 GS)

Berube S, Diorio C, Masse B, Hebert-Croteau N, Byrne C, Cote G, Pollak M, Yaffe M, Brisson J. Vitamin D and calcium intakes from food or supplements and mammographic breast density. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul;14(7):1653-9. (13 ISI, 7 GS)

Berwick M, Armstrong BK, Ben-Porat L, Fine J, Krickler A, Eberle C, Barnhill R. Sun exposure and mortality from melanoma. *J Natl Cancer Inst.* 2005 Feb 2;97(3):195-9. (36 ISI, 92 GS)

Berwick M, Kesler D. Ultraviolet radiation exposure, vitamin D, and cancer. *Photochem Photobiol.* 2005 Nov-Dec;81(6):1261-6. Review.

Chang ET, Blomqvist P, Lambe M. Seasonal variation in the diagnosis of Hodgkin lymphoma in Sweden. *Int J Cancer.* 2005 May 20;115(1):127-30.

Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2005 Oct;14(10):2335-9. (15 ISI)

Crescioli C, Morelli A, Adorini L, Ferruzzi P, Luconi M, Vannelli GB, Marini M, Gelmini S, Fibbi B, Donati S, Villari D, Forti G, Colli E, Andersson KE, Maggi M. Human bladder as a novel target for vitamin D receptor ligands. *J Clin Endocrinol Metab.* 2005 Feb;90(2):962-72. (13 ISI)

Cross HS, Bises G, Lechner D, Manhardt T, Kallay E. The Vitamin D endocrine system of the gut--its possible role in colorectal cancer prevention. *J Steroid Biochem Mol Biol.* 2005 Oct;97(1-2):121-8. (16 ISI)

Dixon KM, Deo SS, Wong G, Slater M, Norman AW, Bishop JE, Posner GH, Ishizuka S, Halliday GM, Reeve VE, Mason RS. Skin cancer prevention: a possible role of 1,25-dihydroxyvitamin D3 and its analogs. *J Steroid Biochem Mol Biol.* 2005 Oct;97(1-2):137-43. (19 ISI)

Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. *J Mol Biol.* 2005 Jun 3;349(2):248-60. (8 ISI)

Egan KM, Sosman JA, Blot WJ. Sunlight and reduced risk of cancer: is the real story vitamin D? *J Natl Cancer Inst.* 2005 Feb 2;97(3):161-3. (23 ISI, 40 GS)

Flood A, Peters U, Chatterjee N, Lacey JV Jr, Schairer C, Schatzkin A. Calcium from diet and supplements is associated with reduced risk of colorectal cancer in a prospective cohort of women. *Cancer Epidemiol Biomarkers Prev.* 2005 Jan;14(1):126-32. (8 ISI)

Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. *J Endocrinol.* 2005 Jun;185(3):577-92. (10 ISI, 1 GS)

Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). *Cancer Causes Control.* 2005 Mar;16(2):83-95. Review. (77 ISI, 81 GS)

Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. *FASEB J.* 2005 Jul;19(9):1067-77. (24 ISI)

Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF. Vitamin D and prevention of colorectal cancer. *J Steroid Biochem Mol Biol.* 2005 Oct;97(1-2):179-94. (48 ISI, 43 GS)

Grant WB, Garland CF, Holick MF. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. *Photochem Photobiol.* 2005;81:1276-86. (25 ISI, 17 GS)

Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. *Altern Med Rev.* 2005;10:94-111. (59 ISI, 45 GS)

Gross MD. Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. *J Nutr.* 2005 Feb;135(2):326-31. Review. (16 ISI, 8 GS)

- Hartman TJ, Albert PS, Snyder K, Slattery ML, Caan B, Paskett E, Iber F, Kikendall JW, Marshall J, Shike M, Weissfeld J, Brewer B, Schatzkin A, Lanza E; Polyp Prevention Study Group. The association of calcium and vitamin D with risk of colorectal adenomas. *J Nutr.* 2005 Feb;135(2):252-9. (15 ISI)
- Hayes VM, Severi G, Padilla EJ, Eggleston SA, Southey MC, Sutherland RL, Hopper JL, Giles GG. Genetic variants in the vitamin D receptor gene and prostate cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2005 Apr;14(4):997-9. (10 ISI, 28 GS)
- Heaney RP. The Vitamin D requirement in health and disease. *J Steroid Biochem Mol Biol.* 2005 Oct;97(1-2):13-9. (32 GS)
- Holick MF. The vitamin D epidemic and its health consequences. *J Nutr.* 2005 Nov;135(11):2739S-48S. (22 ISI, 29 GS)
- Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. *J Nutr.* 2005 Feb;135(2):317-22. (34 ISI, 80 GS)
- Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. *Cancer Epidemiol Biomarkers Prev.* 2005 Mar;14(3):590-5. (13 ISI, 17 GS)
- John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. *Cancer Res.* 2005 Jun 15;65(12):5470-9. (48 ISI, 43 GS)
- Jurutka PW, Thompson PD, Whitfield GK, Eichhorst KR, Hall N, Dominguez CE, Hsieh JC, Haussler CA, Haussler MR. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. *J Cell Biochem.* 2005 Apr 1;94(5):917-43. (11 ISI)
- Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf. *Angiogenesis.* 2005;8(4):349-60.
- Kallay E, Bises G, Bajna E, Bieglmayer C, Gerdenitsch W, Steffan I, Kato S, Armbrecht HJ, Cross HS. Colon-specific regulation of vitamin D hydroxylases—a possible approach for tumor prevention. *Carcinogenesis.* 2005 Sep;26(9):1581-9. (6 ISI)
- Kesse E, Boutron-Ruault MC, Norat T, Riboli E, Clavel-Chapelon F; E3N Group. Dietary calcium, phosphorus, vitamin D, dairy products and the risk of colorectal adenoma and cancer among French women of the E3N-EPIC prospective study. *Int J Cancer.* 2005 Oct 20;117(1):137-44. (15 ISI)
- Lin J, Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE. Intakes of calcium and vitamin D and risk of colorectal cancer in women. *Am J Epidemiol.* 2005 Apr 15;161(8):755-64. (10 ISI, 12 GS)
- Liu Z, Calderon JI, Zhang Z, Sturgis EM, Spitz MR, Wei Q. Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer. *Pharmacogenet Genomics.* 2005 Mar;15(3):159-65.
- Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. *Eur J Cancer.* 2005 May;41(8):1164-9. (32 ISI, 8 GS)
- Matilainen M, Malinen M, Saavalainen K, Carlberg C. Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. *Nucleic Acids Res.* 2005 Sep 26;33(17):5521-32. (15 ISI)
- Matusiak D, Murillo G, Carroll RE, Mehta RG, Benya RV. Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. *Cancer Epidemiol Biomarkers Prev.* 2005 Oct;14(10):2370-6.
- McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL, Thun MJ, Calle EE. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev.* 2005 Dec;14(12):2898-904. (18 ISI)
- Moan J, Porojnicu AC, Røksahm TE, Dahlback A, Juzeniene A, Tretli S, Grant W. Solar radiation, vitamin D and survival rate of colon cancer in Norway. *J Photochem Photobiol B.* 2005 Mar 1;78(3):189-93. (37 ISI, 28 GS)

- Moon SJ, Fryer AA, Strange RC. Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. *Mutat Res.* 2005 Apr 1;571(1-2):207-19. (8 ISI, 12 GS)
- Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. *Cancer Res.* 2005 Sep 1;65(17):7917-25. (11 ISI)
- Mosekilde L. Vitamin D and the elderly. *Clin Endocrinol (Oxf).* 2005 Mar;62(3):265-81. (60 ISI, 34 GS)
- Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? *Endocr Rev.* 2005 Dec;26(7):898-915. (22 ISI)
- Murthy S, AgoulNIK IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. *Prostate.* 2005 Sep 1;64(4):362-72.
- Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. *Carcinogenesis.* 2005 Feb;26(2):429-40. (14 ISI)
- Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. *Endocr Rev.* 2005 Aug;26(5):662-87. (63 ISI)
- Ordóñez-Moran P, Larriba MJ, Pendas-Franco N, Aguilera O, Gonzalez-Sancho JM, Muñoz A. Vitamin D and cancer: an update of in vitro and in vivo data. *Front Biosci.* 2005 Sep 1;10:2723-49. (17 ISI)
- Peehl DM, Feldman D. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. *J Steroid Biochem Mol Biol.* 2004 Nov;92(4):307-15. (8 GS)
- Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. *Eur J Clin Invest.* 2005 May;35(5):290-304. Review. (53 ISI, 34 GS)
- Porojnicu AC, Robsahm TE, Ree AH, Moan J. Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D. *Br J Cancer.* 2005 Sep 5;93(5):571-4. (27 ISI, 16 GS)
- Salazar-Martinez E, Lazcano-Ponce E, Sanchez-Zamorano LM, Gonzalez-Lira G, Escudero-DE Los Rios P, Hernandez-Avila M. Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico. *Int J Gynecol Cancer.* 2005 Sep-Oct;15(5):938-45. (6 ISI)
- Schwartz GG. Vitamin D and the epidemiology of prostate cancer. *Semin Dial.* 2005 Jul-Aug;18(4):276-89. (17 ISI, 13 GS)
- Segersten U, Holm PK, Björklund P, Hessman O, Nordgren H, Binderup L, Akerström G, Hellman P, Westin G. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. *Breast Cancer Res.* 2005;7(6):R980-6.
- Sinkkonen L, Malinen M, Saavalainen K, Vaisanen S, Carlberg C. Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter. *Nucleic Acids Res.* 2005 Apr 29;33(8):2440-51. (7 ISI)
- Smedby KE, Hjalgrim H, Melbye M, Torrang A, Rostgaard K, Munksgaard L, Adami J, Hansen M, Porwit-MacDonald A, Jensen BA, Roos G, Pedersen BB, Sundström C, Glimelius B, Adami HO. Ultraviolet radiation exposure and risk of malignant lymphomas. *J Natl Cancer Inst.* 2005 Feb 2;97(3):199-209. (63 ISI, 81 GS)
- Spina C, Tangpricha V, Yao M, Zhou W, Wolfe MM, Maehr H, Uskokovic M, Adorini L, Holick MF. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. *J Steroid Biochem Mol Biol.* 2005 Oct;97(1-2):111-20. (10 ISI, 3 GS)
- Swami S, Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. *Mol Cell Endocrinol.* 2005 Sep 28;241(1-2):49-61. (11 ISI)
- Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM, Holick MF. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. *J Nutr.* 2005 Oct;135(10):2350-4. (10 ISI)

Tavani A, Bertuccio P, Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. *Eur Urol*. 2005 Jul;48(1):27-33. (7 ISI)

Tokar EJ, Webber MM. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. *Clin Exp Metastasis*. 2005;22(3):265-73. (7 ISI)

Tokar EJ, Webber MM. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. *Clin Exp Metastasis*. 2005;22(3):275-84.

Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M. Autocrine metabolism of vitamin D in normal and malignant breast tissue. *Clin Cancer Res*. 2005 May 1;11(9):3579-86. (37 ISI, 17 GS)

Townsend K, Evans KN, Campbell MJ, Colston KW, Adams JS, Hewison M. Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. *J Steroid Biochem Mol Biol*. 2005 Oct;97(1-2):103-9. (23 ISI, 2 GS)

Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. *Am J Clin Nutr*. 2005 May;81(5):1147-54. (14 ISI)

Tuohimaa P, Golovko O, Kalueff A, Nazarova N, Qiao S, Syvala H, Talonpoika R, Lou YR. Calcidiol and prostate cancer. *J Steroid Biochem Mol Biol*. 2005 Feb;93(2-5):183-90.

Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, Konstorium A, Lallemant B, Zhang R, Mader S, White JH. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. *Mol Endocrinol*. 2005 Nov;19(11):2685-95. (43 ISI)

Whiting SJ, Calvo MS. Dietary recommendations to meet both endocrine and autocrine needs of Vitamin D. *J Steroid Biochem Mol Biol*. 2005 Oct;97(1-2):7-12. (9 ISI)

Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. *Nutr Cancer*. 2005;51(1):32-6. (11 ISI)

Yee YK, Chintalacharuvu SR, Lu J, Nagpal S. Vitamin D receptor modulators for inflammation and cancer. *Mini Rev Med Chem*. 2005 Aug;5(8):761-78.

Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev*. 2005 Oct;14(10):2303-9. (35 ISI, 17 GS).



(11+ citat) (64 papers, 38≥20)

Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. *Oncogene*. 2004 Apr 22;23(19):3350-60. (22 ISI)

Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. *Mol Cancer Ther*. 2004 Mar;3(3):373-81. Review. (37 ISI)

Berube S, Diorio C, Verhoek-Oftedahl W, Brisson J. Vitamin D, calcium, and mammographic breast densities. *Cancer Epidemiol Biomarkers Prev*. 2004 Sep;13(9):1466-72. (32 ISI, 21 GS)

Bises G, Kallay E, Weiland T, Wrba F, Wenzl E, Bonner E, Kriwanek S, Obrist P, Cross HS. 25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. *J Histochem Cytochem*. 2004 Jul;52(7):985-9. (27 ISI)

- Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. *Environ Mol Mutagen*. 2004;43(2):121-7. (32 ISI, 27 GS)
- Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. *Am J Clin Nutr*. 2004 Dec;80(6 Suppl):1717S-20S.
- Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA. Vitamin D receptor gene polymorphisms and prostate cancer risk. *Prostate*. 2004 Jun 1;59(4):409-18. (19 ISI; 19 GS)
- Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, Colditz GA, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Miller AB, Pietinen P, Potter JD, Rohan TE, Terry P, Toniolo P, Virtanen MJ, Willett WC, Wolk A, Wu K, Yaun SS, Zeleniuch-Jacquotte A, Hunter DJ. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. *J Natl Cancer Inst*. 2004 Jul 7;96(13):1015-22. Erratum in: *J Natl Cancer Inst*. 2004 Nov 17;96(22):1724. (61 ISI, 50 GS)
- Coyle YM. The effect of environment on breast cancer risk. *Breast Cancer Res Treat*. 2004 Apr;84(3):273-88. (29 ISI, 23 GS)
- Cross HS, Kallay E, Lechner D, Gerdenitsch W, Adlercreutz H, Armbrrecht HJ. Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. *J Nutr*. 2004 May;134(5):1207S-1212S. Review. (33 ISI, 30 GS)
- Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, Giovannucci EL. Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev*. 2004 Sep;13(9):1502-8. (54 ISI, 24 GS)
- Grant WB. A multicountry ecologic study of risk and risk reduction factors for prostate cancer mortality. *Eur Urol*. 2004 Mar;45(3):271-9. (18 ISI, 41 GS)
- Grant WB, Garland CF. A critical review of studies on vitamin D in relation to colorectal cancer. *Nutr Cancer*. 2004;48(2):115-23. (48 ISI, 49 GS)
- Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, Wilson RG, Thomas V, Colston KW. Vitamin D receptor gene polymorphisms and breast cancer risk. *Clin Cancer Res*. 2004 Aug 15;10(16):5472-81. (21 ISI, 11 GS)
- Guzey M, Luo J, Getzenberg RH. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells. *J Cell Biochem*. 2004 Oct 1;93(2):271-85. (12 ISI)
- Harris DM, Go VL. Vitamin D and colon carcinogenesis. *J Nutr*. 2004 Dec;134(12 Suppl):3463S-3471S. (22 ISI, 18 GS)
- Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. *Mol Cell Endocrinol*. 2004 Feb 27;215(1-2):31-8. Review. (31 ISI)
- Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. *Am J Clin Nutr*. 2004 Mar;79(3):362-71. Review. Erratum in: *Am J Clin Nutr*. 2004 May;79(5):890. (169 ISI, 220 GS)
- Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr*. 2004 Dec;80(6 Suppl):1678S-88S. Review. (75 ISI, 158 GS)
- Hu S, Ma F, Collado-Mesa F, Kirsner RS. Ultraviolet radiation and incidence of non-Hodgkin's lymphoma among Hispanics in the United States. *Cancer Epidemiol Biomarkers Prev*. 2004 Jan;13(1):59-64. (21 ISI, 21 GS)
- Huang SP, Chou YH, Wayne Chang WS, Wu MT, Chen YY, Yu CC, Wu TT, Lee YH, Huang JK, Wu WJ, Huang CH. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. *Cancer Lett*. 2004 Apr 15;207(1):69-77.
- Huang YC, Chen JY, Hung WC. Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. *Oncogene*. 2004 Jun 17;23(28):4856-61. (15 ISI)

- Hughes AM, Armstrong BK, Vajdic CM, Turner J, Grulich A, Fritschi L, Milliken S, Kaldor J, Benke G, Krickler A. Pigmentary characteristics, sun sensitivity and non-Hodgkin lymphoma. *Int J Cancer*. 2004 Jun 20;110(3):429-34.
- Hughes AM, Armstrong BK, Vajdic CM, Turner J, Grulich AE, Fritschi L, Milliken S, Kaldor J, Benke G, Krickler A. Sun exposure may protect against non-Hodgkin lymphoma: a case-control study. *Int J Cancer*. 2004 Dec 10;112(5):865-71. (51 ISI, 70 GS)
- Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):533-7. (23 ISI)
- Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. *J Biol Chem*. 2004 Dec 17;279(51):53213-21. (12 ISI)
- John EM, Dreon DM, Koo J, Schwartz GG. Residential sunlight exposure is associated with a decreased risk of prostate cancer. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):549-52. (22 ISI)
- Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM, Campbell MJ. Altered SMRT levels disrupt vitamin D3 receptor β signaling in prostate cancer cells. *Oncogene*. 2004 Sep 2;23(40):6712-25. (28 ISI)
- Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. *Curr Opin Urol*. 2004 May;14(3):143-9. (33 ISI)
- Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. *Prostate*. 2004 May 15;59(3):243-51. (26 ISI)
- Lehmann B, Querings K, Reichrath J. Vitamin D and skin: new aspects for dermatology. *Exp Dermatol*. 2004;13 Suppl 4:11-5. (17 ISI, 20 GS)
- Lin R, White JH. The pleiotropic actions of vitamin D. *Bioessays*. 2004 Jan;26(1):21-8. Review. (49 ISI)
- Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D, Peehl DM. Mechanisms of decreased Vitamin D 1 α -hydroxylase activity in prostate cancer cells. *Mol Cell Endocrinol*. 2004 Jun 30;221(1-2):67-74. (11 ISI)
- McCullough ML, Robertson AS, Rodriguez C, Jacobs EJ, Chao A, Carolyn J, Calle EE, Willett WC, Thun MJ. Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). *Cancer Causes Control*. 2003 Feb;14(1):1-12. (34 ISI, 26 GS)
- Miettinen S, Ahonen MH, Lou YR, Manninen T, Tuohimaa P, Syvala H, Ylikomi T. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. *Int J Cancer*. 2004 Jan 20;108(3):367-73. (16 ISI, 14 GS)
- Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D 4th, Holly EA, Sagebiel RW, Potischman N. Diet and melanoma in a case-control study. *Cancer Epidemiol Biomarkers Prev*. 2004 Jun;13(6):1042-51. (32 ISI, 26 GS)
- Mitschele T, Diesel B, Friedrich M, Meineke V, Maas RM, Gartner BC, Kamradt J, Meese E, Tilgen W, Reichrath J. Analysis of the vitamin D system in basal cell carcinomas (BCCs). *Lab Invest*. 2004 Jun;84(6):693-702. (7 GS)
- Mizoue T. Ecological study of solar radiation and cancer mortality in Japan. *Health Phys*. 2004 Nov;87(5):532-8. (20 ISI, 18 GS)
- Murthy S, Weigel NL. 1 α ,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. *Prostate*. 2004 May 15;59(3):282-91.
- Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T. Metastatic growth of lung cancer cells is extremely reduced in Vitamin D receptor knockout mice. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):545-7.
- Nishinaka Y, Masutani H, Oka S, Matsuo Y, Yamaguchi Y, Nishio K, Ishii Y, Yodoi J. Importin α 1 (Rch1) mediates nuclear translocation of thioredoxin-binding protein-2/vitamin D(3)-up-regulated protein 1. *J Biol Chem*. 2004 Sep 3;279(36):37559-65. (25 ISI)

Palmer HG, Larriba MJ, Garcia JM, Ordonez-Moran P, Pena C, Peiro S, Puig I, Rodriguez R, de la Fuente R, Bernad A, Pollan M, Bonilla F, Gamallo C, de Herreros AG, Munoz A. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. *Nat Med*. 2004 Sep;10(9):917-9. (53 ISI)

Peng L, Malloy PJ, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. *Mol Endocrinol*. 2004 May;18(5):1109-19. (29 ISI)

Peters U, Hayes RB, Chatterjee N, Shao W, Schoen RE, Pinsky P, Hollis BW, McGlynn KA; Prostate, Lung, Colorectal and Ovarian Cancer Screening Project Team. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev*. 2004 Apr;13(4):546-52. (11 ISI)

Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. *Cancer Causes Control*. 2004 Apr;15(3):255-65. (33 ISI, 19 GS)

Pourgholami MH, Morris DL. 1,25-Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):513-8. Review

Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. *Cancer Res*. 2004 Mar 15;64(6):2143-7. (13 ISI, 16 GS)

Reichrath J, Rafi L, Rech M, Mitschele T, Meineke V, Gärtner BC, Tilgen W, Holick MF. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. *J Cutan Pathol*. 2004 Mar;31(3):224-31.

Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). *Cancer Causes Control*. 2004 Mar;15(2):149-58. (77 ISI, 65 GS)

Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. *Carcinogenesis*. 2004 Jun;25(6):1015-26. (12 ISI)

Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):375-9.

Sillanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrinen K. Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk. *Pharmacogenetics*. 2004 Apr;14(4):239-45.

Slattery ML, Neuhausen SL, Hoffman M, Caan B, Curtin K, Ma KN, Samowitz W. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. *Int J Cancer*. 2004 Sep 20;111(5):750-6. Erratum in: *Int J Cancer*. 2004 Oct 10;111(6):983. (31 ISI)

Stewart LV, Weigel NL. Vitamin D and prostate cancer. *Exp Biol Med (Maywood)*. 2004 Apr;229(4):277-84. Review. (22 ISI, 20 GS)

Tangpricha V, Colon NA, Kaul H, Wang SL, Decastro S, Blanchard RA, Chen TC, Holick MF. Prevalence of vitamin D deficiency in patients attending an outpatient cancer care clinic in Boston. *Endocr Pract*. 2004 May-Jun;10(3):292-3. (29 ISI)

Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakhri M, Yu WD, Johnson CS. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):519-26. Review. (47 ISI)

Tseng M, Breslow RA, DeVellis RF, Ziegler RG. Dietary patterns and prostate cancer risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study cohort. *Cancer Epidemiol Biomarkers Prev*. 2004 Jan;13(1):71-7. (11+ ISI, 9 GS)

Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. *Int J Cancer*. 2004 Jan 1;108(1):104-8. (81 ISI, 73 GS)

Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. *Gene*. 2004 Sep 1;338(2):143-56. Review. (56 ISI)

Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):575-9. Review. (40 ISI, 51 GS)

Wallace K, Baron JA, Cole BF, Sandler RS, Karagas MR, Beach MA, Haile RW, Burke CA, Pearson LH, Mandel JS, Rothstein R, Snover DC. Effect of calcium supplementation on the risk of large bowel polyps. *J Natl Cancer Inst*. 2004 Jun 16;96(12):921-5. (23 ISI)

Welsh J. Vitamin D and breast cancer: insights from animal models. *Am J Clin Nutr*. 2004 Dec;80(6 Suppl):1721S-4S. Review. (27 ISI, 17 GS)

Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF, Chen TC. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. *Carcinogenesis*. 2004 Jun;25(6):967-71.

Zinser GM, Welsh J. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. *Carcinogenesis*. 2004 Dec;25(12):2361-72. (22 ISI)



(12+ citat) (45 papers, 23 \geq 28)

Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs—a brief overview. *Mol Cell Biochem*. 2003 Nov;253(1-2):247-54. Review. (33 ISI, 16 GS)

Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. *J Clin Oncol*. 2003 Jan 1;21(1):123-8. (108 ISI, 92 GS)

Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. *Cancer*. 2003 Mar 1;97(5):1217-24. (45 ISI)

Bidoli E, Bosetti C, La Vecchia C, Levi F, Parpinel M, Talamini R, Negri E, Maso LD, Franceschi S. Micronutrients and laryngeal cancer risk in Italy and Switzerland: a case-control study. *Cancer Causes Control*. 2003 Jun;14(5):477-84.

Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Ramachandran S, Fryer AA, Strange RC. Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. *Carcinogenesis*. 2003 Apr;24(4):711-7. (20 ISI, 20 GS)

Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC. Associations between prostate cancer susceptibility and parameters of exposure to ultraviolet radiation. *Cancer Lett*. 2003 Oct 28;200(2):141-8. (27 ISI, 29 GS)

Bodiwala D, Luscombe CJ, Liu S, Saxby M, French M, Jones PW, Fryer AA, Strange RC. Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. *Cancer Lett*. 2003 Mar 31;192(2):145-9. (24 ISI, 28 GS)

Calvo MS, Whiting SJ. Prevalence of vitamin D insufficiency in Canada and the United States: importance to health status and efficacy of current food fortification and dietary supplement use. *Nutr Rev*. 2003 Mar;61(3):107-13. (35 ISI)

Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. *Trends Endocrinol Metab*. 2003 Nov;14(9):423-30. Review. (38 ISI, 39 GS)

Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. *J Cell Biochem*. 2003 Feb 1;88(2):315-22. (35 ISI, 12 GS)

Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. *J Cell Biochem.* 2003 Mar 1;88(4):695-705. Review. (66 ISI)

Farhan H, Wahala K, Cross HS. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. *J Steroid Biochem Mol Biol.* 2003 Mar;84(4):423-9. (17 ISI, 12 GS)

Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. *J Steroid Biochem Mol Biol.* 2003 Feb;84(2-3):181-92.

Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. *Recent Results Cancer Res.* 2003;164:239-46. (25 GS)

Garland CF, Garland FC, Gorham ED. Epidemiologic evidence for different roles of ultraviolet A and B radiation in melanoma mortality rates. *Ann Epidemiol.* 2003 Jul;13(6):395-404. (12 GS)

Grant WB. Ecologic studies of solar UV-B radiation and cancer mortality rates. *Recent Results Cancer Res.* 2003;164:371-7. (44 ISI, 56 GS)

Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR, Heber D. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. *J Natl Cancer Inst.* 2003 Dec 3;95(23):1765-71. (67 ISI, 66 GS)

Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. *Nutr Rev.* 2003 Jul;61(7):227-38. (40 ISI)

Healy KD, Zella JB, Prahil JM, DeLuca HF. Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium. *Proc Natl Acad Sci U S A.* 2003 Aug 19;100(17):9733-7.

Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. *Am J Clin Nutr.* 2003 Nov;78(5):912-9. (51 ISI, 61 GS)

Holick MF. Vitamin D: A millenium perspective. *J Cell Biochem.* 2003 Feb 1;88(2):296-307. (181 ISI, 164 GS)

Jiang F, Li P, Fornace AJ Jr, Nicosia SV, Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. *J Biol Chem.* 2003 Nov 28;278(48):48030-40. (29 ISI, 10 GS)

Kamradt J, Rafi L, Mitschele T, Meineke V, Gärtner BC, Wolfgang T, Holick MF, Reichrath J. Analysis of the vitamin D system in cutaneous malignancies. *Recent Results Cancer Res.* 2003;164:259-69.

Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. *J Cell Biochem.* 2003 Feb 1;88(2):363-71. Review. (61 ISI; 47 GS)

Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. *Nat Rev Cancer.* 2003 Aug;3(8):601-14. (116 ISI)

Langagergaard V, Norgard B, Mellemkjaer L, Pedersen L, Rothman KJ, Sorensen HT. Seasonal variation in month of birth and diagnosis in children and adolescents with Hodgkin disease and non-Hodgkin lymphoma. *J Pediatr Hematol Oncol.* 2003 Jul;25(7):534-8.

Lieberman DA, Prindiville S, Weiss DG, Willett W; VA Cooperative Study Group 380. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. *JAMA.* 2003 Dec 10;290(22):2959-67. (54 ISI)

Liu G, Wilding G, Staab MJ, Horvath D, Miller K, Dresen A, Alberti D, Arzoomanian R, Chappell R, Bailey HH. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. *Clin Cancer Res.* 2003 Sep 15;9(11):4077-83. (15 ISI)

McCullough ML, Robertson AS, Rodriguez C, Jacobs EJ, Chao A, Carolyn J, Calle EE, Willett WC, Thun MJ. Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). *Cancer Causes Control.* 2003 Feb;14(1):1-12. (52 ISI, 53 GS)

Norat T, Riboli E. Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence. *Eur J Clin Nutr.* 2003 Jan;57(1):1-17. (41 ISI)

Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2003 Dec;12(12):1395-402. (38 ISI, 32 GS)

Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, Larriba MJ, Cordon-Cardo C, Munoz A. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. *Cancer Res.* 2003 Nov 15;63(22):7799-806. (40 ISI)

Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. *J Nutr.* 2003 Jul;133(7 Suppl):2461S-2469S. (25 ISI, 21 GS)

Ravid A, Koren R. The role of reactive oxygen species in the anticancer activity of vitamin D. *Recent Results Cancer Res.* 2003;164:357-67.

Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, Thun MJ, Calle EE. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. *Cancer Epidemiol Biomarkers Prev.* 2003 Jul;12(7):597-603. (49 ISI)

Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. *Int J Cancer.* 2003 Oct 20;107(1):60-4. (35 ISI)

Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. *Breast Cancer Res Treat.* 2003 Jul;80(1):49-62. (48 ISI)

Weitsman GE, Ravid A, Liberman UA, Koren R. Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. *Ann N Y Acad Sci.* 2003 Dec;1010:437-40. (14 GS)

Weitsman GE, Ravid A, Liberman UA, Koren R. Vitamin D enhances caspase-dependent and -independent TNFalpha-induced breast cancer cell death: The role of reactive oxygen species and mitochondria. *Int J Cancer.* 2003 Aug 20;106(2):178-86.

Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ. Vitamin D-3 receptor as a target for breast cancer prevention. *J Nutr.* 2003 Jul;133(7 Suppl):2425S-2433S. Review. (23 GS)

Wong HL, Seow A, Arakawa K, Lee HP, Yu MC, Ingles SA. Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. *Carcinogenesis.* 2003 Jun;24(6):1091-5. (27 ISI, 22 GS)

Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. *Cancer Epidemiol Biomarkers Prev.* 2003 Jan;12(1):23-7. (26 ISI)

Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. *J Biol Chem.* 2003 Nov 21;278(47):46862-8. (28 ISI)

Yokomura K, Suda T, Sasaki S, Inui N, Chida K, Nakamura H. Increased expression of the 25-hydroxyvitamin D(3)-1alpha-hydroxylase gene in alveolar macrophages of patients with lung cancer. *J Clin Endocrinol Metab.* 2003 Dec;88(12):5704-9.

Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? *Br J Nutr.* 2003 May;89(5):552-72. (185 ISI, 145 GS)



(25+ citat) (36 papers, 21 >35)

Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. *Endocrinology*. 2002 Jul;143(7):2508-14. (33 ISI)

Bortman P, Folgueira MA, Katayama ML, Snitcovsky IM, Brentani MM. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. *Braz J Med Biol Res*. 2002 Jan;35(1):1-9.

Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. *Endocr Relat Cancer*. 2002 Mar;9(1):45-59. (59 ISI; 49 GS)

Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. *Ann Epidemiol*. 2002 Apr;12(3):182-96. Review. (40 ISI)

Freedman DM, Dosemeci M, McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. *Occup Environ Med*. 2002 Apr;59(4):257-62. (105 ISI, 64 GS)

Friedrich M, Villena-Heinsen C, Axt-Flidner R, Meyberg R, Tilgen W, Schmidt W, Reichrath J. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in cervical tissue. *Anticancer Res*. 2002 Jan-Feb;22(1A):183-6.

Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. *Cancer*. 2002 Jan 1;94(1):272-81. (59 ISI, 103 GS)

Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. *Cancer*. 2002 Mar 15;94(6):1867-75. (180 ISI, 210 GS)

Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marberger M, Vutuc C, Micksche M. Vitamin D receptor gene polymorphism and prostate cancer risk. *Prostate*. 2002 Apr 1;51(1):30-4. (28 GS)

Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. *Mol Cancer Ther*. 2002 Jul;1(9):667-77. (50 ISI)

Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. *Urol Int*. 2002;68(4):226-31.

Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA, Moss SF, Kurihara N, Fan K, Yang K, Lipkin M. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. *Cancer Epidemiol Biomarkers Prev*. 2002 Jan;11(1):113-9. (56 ISI, 45 GS)

Ikuyama T, Hamasaki T, Inatomi H, Katoh T, Muratani T, Matsumoto T. Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese. *Endocr J*. 2002 Aug;49(4):433-8.

Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. *Cancer Metastasis Rev*. 2002;21(2):147-58. (30 GS)

Kristal AR, Cohen JH, Qu P, Stanford JL. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2002 Aug;11(8):719-25. (51 ISI, 43 GS)

Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. *Science*. 2002 May 17;296(5571):1313-6. (226 ISI, 155 GS)

Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW, Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. *J Biol Chem*. 2002 Aug 23;277(34):30738-45. (77 ISI, 61 GS)

McIntyre H, Blue J, Harman J. A seasonal variation in breast cancer. *N Z Med J*. 2002 Jul 2;115(1157):U45.

- Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. *J Hum Genet.* 2002;47(8):413-8. (25 ISI, 36 GS)
- Mehta RG, Mehta RR. Vitamin D and cancer. *J Nutr Biochem.* 2002 May;13(5):252-264. (38 ISI, 28 GS)
- Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. *Clin Pharmacol Ther.* 2002 Dec;72(6):648-59. (36 ISI)
- Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? *Br J Dermatol.* 2002 Aug;147(2):197-213. Review. (46 ISI, 44 GS)
- Polek TC, Weigel NL. Vitamin D and prostate cancer. *J Androl.* 2002 Jan-Feb;23(1):9-17. (25 GS)
- Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Hernandez-Avila M. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. *Oncology.* 2002;63(2):151-7. (25 ISI)
- Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. *J Natl Cancer Inst.* 2002 Sep 4;94(17):1301-11. (85 ISI, 52 GS)
- Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. *Nat Rev Cancer.* 2002 Jul;2(7):537-43. Review. (81 ISI)
- Terry P, Baron JA, Bergkvist L, Holmberg L, Wolk A. Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. *Nutr Cancer.* 2002;43(1):39-46. (25 ISI)
- Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, Haussler CA, Haussler MR. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. *Biochem Biophys Res Commun.* 2002 Dec 20;299(5):730-8. (33 ISI)
- Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. *FASEB J.* 2002 Jan;16(1):2-14. Review. (101 ISI)
- van den Bermd GJ, Chang GT. Vitamin D and vitamin D analogs in cancer treatment. *Curr Drug Targets.* 2002 Feb;3(1):85-94. (34 ISI, 38 GS)
- Welsh J, Wietzke JA, Zinser GM, Smyczek S, Romu S, Tribble E, Welsh JC, Byrne B, Narvaez CJ. Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. *J Steroid Biochem Mol Biol.* 2002 Dec;83(1-5):85-92. Review. (32 ISI)
- Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. *J Steroid Biochem Mol Biol.* 2002 Jun;81(2):135-40. (29 ISI)
- Wong NA, Pignatelli M. Beta-catenin--a linchpin in colorectal carcinogenesis? *Am J Pathol.* 2002 Feb;160(2):389-401. Review. (133 ISI)
- Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. *J Natl Cancer Inst.* 2002 Mar 20;94(6):437-46. (84 ISI)
- Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. *J Biol Chem.* 2002 Jan 25;277(4):2468-76. (41 ISI)
- Ylikomi T, Laaksi I, Lou YR, Martikainen P, Miettinen S, Pennanen P, Purmonen S, Syvala H, Vienonen A, Tuohimaa P. Antiproliferative action of vitamin D. *Vitam Horm.* 2002;64:357-406. (20 GS)
- Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. *J Am Soc Nephrol.* 2002 Mar;13(3):621-9. (42 ISI)

Zinser G, Packman K, Welsh J. Vitamin D(3) receptor ablation alters mammary gland morphogenesis. *Development*. 2002 Jul;129(13):3067-76. (33 ISI)



(28+ citat) (35 papers, 23>40)

Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, White JH. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. *Mol Endocrinol*. 2001 Jul;15(7):1127-39. (52 ISI)

Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. *Biochem Biophys Res Commun*. 2001 Jul 27;285(4):1012-7. (47 ISI)

Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. *Cancer*. 2001 Jun 15;91(12):2431-9. (50 ISI)

Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. *J Urol*. 2001 Apr;165(4):1319-24. (63 ISI)

Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. *Br J Cancer*. 2001 Jul 20;85(2):171-5. (28 ISI, 30 GS)

Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. *Epidemiol Rev*. 2001;23(1):87-92. Review. (76 ISI, 76 GS)

Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. *Cancer Res*. 2001 Jun 1;61(11):4333-6. (42 ISI, 36 GS)

Consolini R, Pala S, Legitimo A, Crimaldi G, Ferrari S, Ferrari S. Effects of vitamin D on the growth of normal and malignant B-cell progenitors. *Clin Exp Immunol*. 2001 Nov;126(2):214-9.

Cross HS, Bareis P, Hofer H, Bischof MG, Bajna E, Kriwanek S, Bonner E, Peterlik M. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. *Steroids*. 2001 Mar-May;66(3-5):287-92. (71 ISI)

Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. *Cancer Res*. 2000 Apr 15;60(8):2304-12. (57 ISI)

Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. *Annu Rev Pharmacol Toxicol*. 2001;41:421-42. Review. (40 ISI, 44 GS)

Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. *Endocr J*. 2001 Oct;48(5):543-9.

Hansen CM, Binderup L, Hamberg KJ, Carlberg C. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. *Front Biosci*. 2001 Jul 1;6:D820-48. (33 ISI, 58 GS)

Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. *Clin Cancer Res*. 2001 Apr;7(4):1043-51. (53 ISI)

- Hsu JY, Feldman D, McNeal JE, Peehl DM. Reduced 1 α -hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D₃-induced growth inhibition. *Cancer Res.* 2001 Apr 1;61(7):2852-6. (73 ISI)
- Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J. Inhibitory effects of 1 α ,25-dihydroxyvitamin D₃ on the G(1)-S phase-controlling machinery. *Mol Endocrinol.* 2001 Aug;15(8):1370-80. (43 ISI)
- Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S, Cross HS. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. *Carcinogenesis.* 2001 Sep;22(9):1429-35. (44 ISI)
- Kim KE, Brasitus TA. The role of vitamin D in normal and pathologic processes in the colon. *Curr Opin Gastroenterol.* 2001 Jan;17(1):72-7.
- Konety BR, Lavelle JP, Pirtskalaishvili G, Dhir R, Meyers SA, Nguyen TS, Hersherberger P, Shurin MR, Johnson CS, Trump DL, Zeidel ML, Getzenberg RH. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. *J Urol.* 2001 Jan;165(1):253-8. (24 GS)
- Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, Getzenberg RH. Expression patterns of vitamin D receptor in human prostate. *J Cell Biochem.* 2001;82(4):566-72.
- Lamprecht SA, Lipkin M. Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. *Ann N Y Acad Sci.* 2001 Dec;952:73-87. Review. (36 ISI)
- Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. *Br J Cancer.* 2001 Nov 16;85(10):1504-9. (28 ISI, 28 GS)
- Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW, Strange RC. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. *Lancet.* 2001 Aug 25;358(9282):641-2. (76 GS)
- Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. *J Natl Cancer Inst.* 2001 Sep 5;93(17):1330-6. (58 ISI)
- McGuire TF, Trump DL, Johnson CS. Vitamin D₃-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. *J Biol Chem.* 2001 Jul 13;276(28):26365-73. (48 ISI, 37 GS)
- Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. *J Biol Chem.* 2001 Mar 23;276(12):9101-7. (51 GS)
- Narvaez CJ, Zinser G, Welsh J. Functions of 1 α ,25-dihydroxyvitamin D₃ in mammary gland: from normal development to breast cancer. *Steroids.* 2001 Mar-May;66(3-5):301-8. Review. (46 ISI, 28 GS)
- Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A. Vitamin D₃ promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. *J Cell Biol.* 2001 Jul 23;154(2):369-87. (107 ISI)
- Peters U, McGlynn KA, Chatterjee N, Gunter E, Garcia-Closas M, Rothman N, Sinha R. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. *Cancer Epidemiol Biomarkers Prev.* 2001 Dec;10(12):1267-74. (47 ISI, 49 GS)
- Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR, Campbell MJ. Synergistic growth inhibition of prostate cancer cells by 1 α ,25 Dihydroxyvitamin D₃ and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. *Oncogene.* 2001 Apr 5;20(15):1860-72. (46 ISI)
- Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, Holick MF. 25-hydroxyvitamin D-1 α -hydroxylase in normal and malignant colon tissue. *Lancet.* 2001 May 26;357(9269):1673-4. (75 ISI, 73 GS)

Tuohimaa P, Lyakhovich A, Aksenov N, Pennanen P, Syvala H, Lou YR, Ahonen M, Hasan T, Pasanen P, Blauer M, Manninen T, Miettinen S, Vilja P, Ylikomi T. Vitamin D and prostate cancer. *J Steroid Biochem Mol Biol.* 2001 Jan-Mar;76(1-5):125-34. (28 GS)

van Wijngaarden E, Savitz DA. Occupational sunlight exposure and mortality from non-Hodgkin lymphoma among electric utility workers. *J Occup Environ Med.* 2001 Jun;43(6):548-53.

Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, Haussler CA, Galligan MA, Thatcher ML, Encinas Dominguez C, Haussler MR. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. *Mol Cell Endocrinol.* 2001 May 25;177(1-2):145-59. (65 ISI)

Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. *J Clin Endocrinol Metab.* 2001 Feb;86(2):888-94. (91 ISI)



(39+ citat) (19 papers, 14>46)

Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). *Cancer Causes Control.* 2000 Oct;11(9):847-52. (110 ISI, 120 GS)

Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. *Cancer Epidemiol Biomarkers Prev.* 2000 Mar;9(3):265-70. (49 ISI, 53 GS)

Blazer DG 3rd, Umbach DM, Bostick RM, Taylor JA. Vitamin D receptor polymorphisms and prostate cancer. *Mol Carcinog.* 2000 Jan;27(1):18-23. (44 GS)

Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. *Endocrinology.* 2000 Jan;141(1):10-7. (79 ISI)

Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. *Clin Cancer Res.* 2000 Mar;6(3):901-8. (47 ISI)

Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. *Cancer Res.* 2000 Apr 15;60(8):2304-12. (91 GS)

Feldman D, Zhao XY, Krishnan AV. Vitamin D and prostate cancer. *Endocrinology.* 2000 Jan;141(1):5-9. Review. (59 ISI, 89 GS)

Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O, Kato T. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. *Cancer Res.* 2000 Jan 15;60(2):305-8. (82 ISI, 76 GS)

Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, Jones PW, York C, Strange RC, Fryer AA. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. *Clin Cancer Res.* 2000 Feb;6(2):498-504. (63 ISI, 57 GS)

Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, Haile RW, Coetzee GA. Vitamin D receptor genotype and breast cancer in Latinas (United States). *Cancer Causes Control.* 2000 Jan;11(1):25-30. (47 ISI, 44 GS)

Kampman E, Slattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). *Cancer Causes Control.* 2000 May;11(5):459-66. (59 ISI, 53 GS)

Koli K, Keski-Oja J. 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. *Cell Growth Differ.* 2000 Apr;11(4):221-9. (35 GS)

Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. *Circ Res*. 2000 Aug 4;87(3):214-20. (86 ISI)

Negri E, Franceschi S, Bosetti C, Levi F, Conti E, Parpinel M, La Vecchia C. Selected micronutrients and oral and pharyngeal cancer. *Int J Cancer*. 2000 Apr 1;86(1):122-7. (32 GS)

Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. *J Natl Cancer Inst*. 2000 Dec 20;92(24):2009-17. (77 ISI, 75 GS)

Sarkar A, Saha BK, Basak R, Mukhopadhyay I, Karmakar R, Chatterjee M. Anticlastogenic potential of 1alpha,25-dihydroxyvitamin D3 in murine lymphoma. *Cancer Lett*. 2000 Mar 13;150(1):1-13.

Sung V, Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. *Mol Cell Endocrinol*. 2000 Jun;164(1-2):133-43.

van den Bemd GJ, Pols HA, van Leeuwen JP. Anti-tumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs. *Curr Pharm Des*. 2000 May;6(7):717-32.

Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. *Cancer Res*. 2000 Apr 1;60(7):2040-8. (64 ISI)

Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. *Endocrinology*. 2000 Jul;141(7):2548-56. (48 ISI)

Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. *Epidemiol Rev*. 2000;22(2):203-17. Review. (65 ISI)



(47+ citat) (27 papers, 22>50)

Amir H, Karas M, Giat J, Danilenko M, Levy R, Yermiahu T, Levy J, Sharoni Y. Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. *Nutr Cancer*. 1999;33(1):105-12. (58 ISI)

Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, Rothstein R, Summers RW, Snover DC, Beck GJ, Bond JH, Greenberg ER. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. *N Engl J Med*. 1999 Jan 14;340(2):101-7. (285 ISI, 172 GS)

Chen A, Davis BH, Bissonnette M, Scaglione-Sewell B, Brasitus TA. 1,25-Dihydroxyvitamin D(3) stimulates activator protein-1-dependent Caco-2 cell differentiation. *J Biol Chem*. 1999 Dec 10;274(50):35505-13. (56 ISI)

Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W. Vitamin D receptor polymorphisms as markers in prostate cancer. *Hum Genet*. 1999 Sep;105(3):281-7. (66 ISI, 58 GS)

Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. *Int J Cancer*. 1999 Dec 10;83(6):723-6. (59 ISI, 49 GS)

Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healey CS, Smith N, Pharoah PD, Luben RN, Easton DF, Ponder BA. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. *Carcinogenesis*. 1999 Nov;20(11):2131-5. (51 ISI)

Garland CF, Garland FC, Gorham ED. Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. *Ann N Y Acad Sci*. 1999;889:107-19. Review. (60 ISI, 72 GS)

- Giovannucci E. Dietary influences of 1,25(OH)₂ vitamin D in relation to prostate cancer: a hypothesis. *Cancer Causes Control*. 1998 Dec;9(6):567-82. (82 GS)
- Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D₃) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. *Cancer Res*. 1999 Jun 1;59(11):2644-9. (67 ISI)
- Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N, Ishiguro S. Inhibition of angiogenesis as a mechanism for inhibition by 1 α -hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ of colon carcinogenesis induced by azoxymethane in Wistar rats. *Int J Cancer*. 1999 May 31;81(5):730-3.
- James SY, Williams MA, Newland AC, Colston KW. Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. *Gen Pharmacol*. 1999 Jan;32(1):143-54. (56 GS)
- John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. *Cancer Epidemiol Biomarkers Prev*. 1999 May;8(5):399-406. (110 ISI, 111 GS)
- Konety BR, Johnson CS, Trump DL, Getzenberg RH. Vitamin D in the prevention and treatment of prostate cancer. *Semin Urol Oncol*. 1999 May;17(2):77-84. (46 GS)
- Liel Y, Shany S, Smirnoff P, Schwartz B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. *Endocrinology*. 1999 Jan;140(1):280-5. (52 ISI)
- Lipkin M, Reddy B, Newmark H, Lamprecht SA. Dietary factors in human colorectal cancer. *Annu Rev Nutr*. 1999;19:545-86. (80 ISI, 51 GS)
- Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. *Cancer Epidemiol Biomarkers Prev*. 1999 Mar;8(3):241-8. (75 ISI, 72 GS)
- Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungstrom M, Wingren S. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. *Cancer Res*. 1999 May 15;59(10):2332-4. (50 ISI)
- Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. *Cancer Res*. 1999 Oct 1;59(19):4848-56. (95 GS)
- Niv Y, Sperber AD, Figer A, Igaël D, Shany S, Fraser G, Schwartz B. In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the carcinoma. *Cancer*. 1999 Aug 1;86(3):391-7. (20 GS)
- Peehl DM. Vitamin D and prostate cancer risk. *Eur Urol*. 1999;35(5-6):392-4.
- Pietinen P, Malila N, Virtanen M, Hartman TJ, Tangrea JA, Albanes D, Virtamo J. Diet and risk of colorectal cancer in a cohort of Finnish men. *Cancer Causes Control*. 1999 Oct;10(5):387-96. (108 ISI)
- Ravid A, Rucker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R. 1,25-Dihydroxyvitamin D₃ enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. *Cancer Res*. 1999 Feb 15;59(4):862-7. (60 ISI)
- Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. *Clin Cancer Res*. 1999 Jun;5(6):1339-45. (81 ISI)
- Solomon C, White JH, Kremer R. Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D₃-dependent signal transduction by phosphorylating human retinoid X receptor α . *J Clin Invest*. 1999 Jun;103(12):1729-35. (53 ISI)
- Suzuki S, Takenoshita S, Furukawa H, Tsuchiya A. Antineoplastic activity of 1,25(OH)₂D₃ and its analogue 22-oxacalcitriol against human anaplastic thyroid carcinoma cell lines in vitro. *Int J Mol Med*. 1999 Dec;4(6):611-4.

Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr*. 1999 May;69(5):842-56. (252 ISI, 341 GS)

Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1 α ,25-dihydroxyvitamin D₃ and 9-cis retinoic acid in LNCaP human prostate cancer cells. *Endocrinology*. 1999 Mar;140(3):1205-12. (58 ISI, 58 GS)



(53+ citat) (17 papers, 13>54)

Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden) *Cancer Causes Control*. 1998 Dec;9(6):559-66. (79 ISI, 92 GS)

Douglas S, Cortina-Borja M, Cartwright R. Seasonal variation in the incidence of Hodgkin's disease. *Br J Haematol*. 1998 Dec;103(3):653-62.

Giovannucci E. Dietary influences of 1,25(OH)₂ vitamin D in relation to prostate cancer: a hypothesis. *Cancer Causes Control*. 1998 Dec;9(6):567-82. (73 ISI, 75 GS)

Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Calcium and fructose intake in relation to risk of prostate cancer. *Cancer Res*. 1998 Feb 1;58(3):442-7. (148 ISI)

Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D₃ (calcitriol) *J Urol*. 1998 Jun;159(6):2035-9; discussion 2039-40. Erratum in: *J Urol* 1998 Sep;160(3 Pt 1):840. (121 ISI)

Huynh H, Pollak M, Zhang JC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)₂D₃ and its analog EB1089. *Int J Oncol*. 1998 Jul;13(1):137-43. (54 ISI)

Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. *Cancer Res*. 1998 Apr 15;58(8):1620-3. (73 ISI)

Launoy G, Milan C, Day NE, Pienkowski MP, Gignoux M, Faivre J. Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study. *Int J Cancer*. 1998 Mar 30;76(1):7-12. (35 GS)

Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. *Cancer Epidemiol Biomarkers Prev*. 1998 May;7(5):385-90. (96 ISI)

Martinez ME, Willett WC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. *Cancer Epidemiol Biomarkers Prev*. 1998 Feb;7(2):163-8. Review. (98 ISI)

Miller GJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. *Cancer Metastasis Rev*. 1998-1999;17(4):353-60. Review. (52 GS)

Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) *Cancer Causes Control*. 1998 Aug;9(4):425-32. (47 ISI, 52 GS)

Ruggiero M, Pacini S, Aterini S, Fallai C, Ruggiero C, Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. *Oncol Res*. 1998;10(1):43-6.

Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D₃ from 25-hydroxyvitamin D₃. *Cancer Epidemiol Biomarkers Prev*. 1998 May;7(5):391-5. (126 ISI, 122 GS)

Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. *N Engl J Med*. 1998 Mar 19;338(12):777-83. (438 GS)

Utiger RD. The need for more vitamin D. *N Engl J Med*. 1998 Mar 19;338(12):828-9. (98 GS)

Weigel NL, Zhang Y. Ligand-independent activation of steroid hormone receptors. *J Mol Med*. 1998 Jun;76(7):469-79. Review. (146 ISI)

Zhuang SH, Burnstein KL. Antiproliferative effect of 1 α ,25-dihydroxyvitamin D₃ in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. *Endocrinology*. 1998 Mar;139(3):1197-207. (120 ISI, 120 GS)



(53+ citat) (13 papers; 10 >57)

Bikle DD. Vitamin D: a calciotropic hormone regulating calcium-induced keratinocyte differentiation. *J Am Acad Dermatol*. 1997 Sep;37(3 Pt 2):S42-52.

Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-dihydroxyvitamin D₃ and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. *Endocrinology*. 1997 Apr;138(4):1491-7. (136 ISI)

Cross HS, Peterlik M, Reddy GS, Schuster I. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D₃-1 α -hydroxylase activity and regulation of side-chain metabolism. *J Steroid Biochem Mol Biol*. 1997 May;62(1):21-8. (60 ISI)

Freedman DM, Zahm SH, Dosemeci M. Residential and occupational exposure to sunlight and mortality from non-Hodgkin's lymphoma: composite (threefold) case-control study. *BMJ*. 1997 May 17;314(7092):1451-5. (33 GS)

Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. *Urology*. 1997 Dec;50(6):999-1006. (86 ISI)

Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. *J Natl Cancer Inst*. 1997 Jan 15;89(2):166-70. (332 ISI, 293 GS)

Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, Shi CY, Yu MC, Ross RK, Coetzee GA. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. *Cancer Epidemiol Biomarkers Prev*. 1997 Feb;6(2):93-8. (86 ISI)

La Vecchia C, Braga C, Negri E, Franceschi S, Russo A, Conti E, Falcini F, Giacosa A, Montella M, Decarli A. Intake of selected micronutrients and risk of colorectal cancer. *Int J Cancer*. 1997 Nov 14;73(4):525-30. (67 ISI)

Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1 α ,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. *Cancer Epidemiol Biomarkers Prev*. 1997 Sep;6(9):727-32. (74 ISI)

Tangrea J, Helzlsouer K, Pietinen P, Taylor P, Hollis B, Virtamo J, Albanes D. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. *Cancer Causes Control*. 1997 Jul;8(4):615-25. (56 GS)

White E, Shannon JS, Patterson RE. Relationship between vitamin and calcium supplement use and colon cancer. *Cancer Epidemiol Biomarkers Prev*. 1997 Oct;6(10):769-74. (84 ISI)

Zhao XY, Ly LH, Peehl DM, Feldman D. 1 α ,25-dihydroxyvitamin D₃ actions in LNCaP human prostate cancer cells are androgen-dependent. *Endocrinology*. 1997 Aug;138(8):3290-8. (72 ISI)

Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. *Mol Cell Endocrinol*. 1997 Jan 3;126(1):83-90. (78 ISI, 66 GS)



(56+ citat) (19 papers, 11>59)

Baudet C, Chevalier G, Chassevent A, Canova C, Filmon R, Larra F, Brachet P, Wion D. 1,25-Dihydroxyvitamin D₃ induces programmed cell death in a rat glioma cell line. *J Neurosci Res*. 1996 Dec 1;46(5):540-50.

Bentham G. Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales. *BMJ* 1996;312:1128-31.

Boutron MC, Faivre J, Marteau P, Couillaud C, Senesse P, Quipourt V. Calcium, phosphorus, vitamin D, dairy products and colorectal carcinogenesis: a French case—control study. *Br J Cancer*. 1996 Jul;74(1):145-51. (59 ISI)

Christakos S, Raval-Pandya M, Wernyj RP, Yang W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D₃. *Biochem J*. 1996 Jun 1;316 (Pt 2):361-71. Review. Erratum in: *Biochem J* 1996 Sep 15;318(Pt 3):1079. (124 ISI)

Danielpour D. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D₃ in NRP-152 rat prostatic epithelial cells. *J Cell Physiol*. 1996 Jan;166(1):231-9. (73 ISI)

Douglas AS, Brown T, Reid D. Infectious mononucleosis and Hodgkin's disease—a similar seasonality. *Leuk Lymphoma*. 1996 Oct;23(3-4):323-31.

Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. *Prostate*. 1996 Mar;28(3):182-94. (75 ISI)

Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 1996 Feb;5(2):121-6. (76 GS)

Hartge P, Devesa SS, Grauman D, Fears TR, Fraumeni JF Jr. Non-Hodgkin's lymphoma and sunlight. *J Natl Cancer Inst*. 1996 Mar 6;88(5):298-300.

Hedlund TE, Moffatt KA, Miller GJ. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D₃ are mediated exclusively through the genomic signaling pathway. *Endocrinology*. 1996 May;137(5):1554-61. (73 ISI)

Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D₃ in the human prostatic carcinoma cell line ALVA-31. *J Steroid Biochem Mol Biol*. 1996 Jun;58(3):277-88. (57 ISI)

James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D₃ and its analogues on induction of apoptosis in breast cancer cells. *J Steroid Biochem Mol Biol*. 1996 Jul;58(4):395-401. (95 ISI, 82 GS)

Kaiser U, Schilli M, Wegmann B, Barth P, Wedel S, Hofmann J, Havemann K. Expression of vitamin D receptor in lung cancer. *J Cancer Res Clin Oncol*. 1996;122(6):356-9. (52 GS)

Kane KF, Langman MJ, Williams GR. Antiproliferative responses to two human colon cancer cell lines to vitamin D₃ are differently modified by 9-cis-retinoic acid. *Cancer Res*. 1996 Feb 1;56(3):623-32. (55 ISI)

Kearney J, Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Wing A, Kampman E, Willett WC. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. *Am J Epidemiol*. 1996 May 1;143(9):907-17. (70 ISI)

Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH. The role of vitamin D in normal prostate growth and differentiation. *Cell Growth Differ*. 1996 Nov;7(11):1563-70. (54 ISI, 40 GS)

Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. *J Invest Dermatol Symp Proc.* 1996 Apr;1(1):97-101.

Martinez ME, Giovannucci EL, Colditz GA, Stampfer MJ, Hunter DJ, Speizer FE, Wing A, Willett WC. Calcium, vitamin D, and the occurrence of colorectal cancer among women. *J Natl Cancer Inst.* 1996 Oct 2;88(19):1375-82. (86 ISI)

Newton R, Roman E, Fear N, Carpenter L. Non-Hodgkin's lymphoma and solar ultraviolet radiation. Data are inconsistent. *BMJ.* 1996 Aug 3;313(7052):298.

Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. *J Steroid Biochem Mol Biol.* 1996 Jul;58(4):367-76. (66 ISI, 46 GS)

Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. *Cancer Res.* 1996 Sep 15;56(18):4108-10. (179 ISI, 155 GS)



(60+ citat) (8 papers >60)

Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. *Endocr Rev.* 1995 Apr;16(2):200-57. (431 GS)

Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States) *Cancer Causes Control.* 1995 May;6(3):235-9. (78 ISI, 82 GS)

Corder EH, Friedman GD, Vogelmann JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. *Cancer Epidemiol Biomarkers Prev.* 1995 Sep;4(6):655-9. (28 GS)

James SY, Mackay AG, Colston KW. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. *J Mol Endocrinol.* 1995 Jun;14(3):391-4. (60 ISI)

Koli K, Keski-Oja J. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. *Cancer Res.* 1995 Apr 1;55(7):1540-6. (64 ISI)

Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. *Clin Cancer Res.* 1995 Sep;1(9):997-1003. (97 ISI)

Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. *Urology.* 1995 Sep;46(3):365-9. (81 ISI)

Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. *Endocrinology.* 1995 Jan;136(1):20-6. (131 ISI)

Studzinski GP, Moore DC. Sunlight—can it prevent as well as cause cancer? *Cancer Res.* 1995 Sep 15;55(18):4014-22. Review. (61 ISI)

Vandewalle B, Hornez L, Wattez N, Revillion F, Lefebvre J. Vitamin-D3 derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. *Int J Cancer.* 1995 Jun 9;61(6):806-11.



(52+ citat) (6>63)

Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, Evans SR. Vitamin D receptors in breast cancer cells. *Breast Cancer Res Treat.* 1994;31(2-3):191-202. (66 ISI, 53 GS)

Demirpence E, Balaguer P, Trousse F, Nicolas JC, Pons M, Gagne D. Antiestrogenic effects of all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms. *Cancer Res.* 1994 Mar 15;54(6):1458-64. (63 ISI)

Kampman E, Giovannucci E, van't Veer P, Rimm E, Stampfer MJ, Colditz GA, Kok FJ, Willett WC. Calcium, vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. *Am J Epidemiol.* 1994 Jan 1;139(1):16-29. Review. (93 ISI)

Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. *Int J Epidemiol.* 1994 Dec;23(6):1133-6. (52 ISI, 68 GS)

Mawer EB, Hayes ME, Heys SE, Davies M, White A, Stewart MF, Smith GN. Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. *J Clin Endocrinol Metab.* 1994 Aug;79(2):554-60. (21 GS ISI)

Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. *Cancer Res.* 1994 Feb 1;54(3):805-10. (287 ISI)

Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. *Anticancer Res.* 1994 May-Jun;14(3A):1077-81. (102 ISI)

Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. *Biochem Cell Biol.* 1994 Nov-Dec;72(11-12):537-45. Review. (75 ISI, 68 GS)



(33+citat) (5>66)

Ainsleigh HG. Beneficial effects of sun exposure on cancer mortality. *Prev Med.* 1993 Jan;22(1):132-40. Review. (33 ISI)

Beatty MM, Lee EY, Glauert HP. Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high fat diets. *J Nutr.* 1993 Jan;123(1):144-52. (38 ISI)

Bostick RM, Potter JD, Sellers TA, McKenzie DR, Kushi LH, Folsom AR. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. *Am J Epidemiol.* 1993 Jun 15;137(12):1302-17. Review. (131 ISI)

Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelmann JH, Orentreich N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. *Cancer Epidemiol Biomarkers Prev.* 1993 Sep-Oct;2(5):467-72. (178 ISI, 149 GS)

Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. *Blood.* 1993 Sep 1;82(5):1383-94. Review. (62 ISI)

Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. *Cancer Res.* 1993 Aug 15;53(16):3712-8. (78 ISI)

Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. *Endocrinology*. 1993 May;132(5):1952-60. (276 ISI)

Wiseman H. Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. *FEBS Lett*. 1993 Jul 12;326(1-3):285-8. (44 ISI)



(61+ citat, 4>69)

Cross HS, Pavelka M, Slavik J, Peterlik M. Growth control of human colon cancer cells by vitamin D and calcium in vitro. *J Natl Cancer Inst*. 1992 Sep 2;84(17):1355-7. (70 ISI)

Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. *Cancer*. 1992 Dec 15;70(12):2861-9. (275 ISI, 268 GS)

Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhy P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. *Cancer Res*. 1992 Feb 1;52(3):515-20. (149 ISI)

Newmark HL, Lipkin M. Calcium, vitamin D, and colon cancer. *Cancer Res*. 1992 Apr 1;52(7 Suppl):2067s-2070s. (82 ISI)

Schwartz GG. Multiple sclerosis and prostate cancer: what do their similar geographies suggest? *Neuroepidemiology*. 1992;11(4-6):244-54. (19 GS)

Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. *Gut*. 1992 Dec;33(12):1660-3. (62 ISI)



(54+ citat, 0>72)

Chang PL, Prince CW. 1 alpha,25-dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. *Cancer Res*. 1991 Apr 15;51(8):2144-50.

Garland CF, Garland FC, Gorham ED. Can colon cancer incidence and death rates be reduced with calcium and vitamin D? *Am J Clin Nutr*. 1991 Jul;54(1 Suppl):193S-201S. (54 ISI, 76 GS)

Krishnan AV, Feldman D. Stimulation of 1,25-dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors. *J Bone Miner Res*. 1991 Oct;6(10):1099-107. (66 ISI)

Lawson-Matthew P, Clayton J, Guiland-Cumming D, Yates A, Preston E, Greaves M, Kanis JA. Vitamin D metabolism in myeloma. *Br J Haematol*. 1989 Sep;73(1):57-60.

Llor X, Jacoby RF, Teng BB, Davidson NO, Sitrin MD, Brasitus TA. K-ras mutations in 1,2-dimethylhydrazine-induced colonic tumors: effects of supplemental dietary calcium and vitamin D deficiency. *Cancer Res*. 1991 Aug 15;51(16):4305-9. (70 ISI)

Meggouh F, Lointier P, Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. *Cancer Res*. 1991 Feb 15;51(4):1227-33. (55 ISI)

Sitrin MD, Halline AG, Abrahams C, Brasitus TA. Dietary calcium and vitamin D modulate 1,2-dimethylhydrazine-induced colonic carcinogenesis in the rat. *Cancer Res*. 1991 Oct 15;51(20):5608-13. (67 ISI)



(59+ citat; 4)

Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. *Prev Med.* 1990 Nov;19(6):614-22. (162 ISI, 151 GS)

Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. *Int J Epidemiol.* 1990 Dec;19(4):820-4. (69 ISI, 72 GS)

Pols HA, Birkenhager JC, Foekens JA, van Leeuwen JP. Vitamin D: a modulator of cell proliferation and differentiation. *J Steroid Biochem Mol Biol.* 1990 Dec 20;37(6):873-6. Review. (81 ISI)

Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). *Anticancer Res.* 1990 Sep-Oct;10(5A):1307-11. (240 ISI, 218 GS)



Archer VE. Latitudinal variation of digestive tract cancers in the US and China. *Nutr Cancer.* 1989;12(3):213-23. (17 ISI)

Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. *Lancet.* 1989 Jan 28;1(8631):188-91. (169 ISI; 86 GS)

Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. *Lancet.* 1989 Nov 18;2(8673):1176-8. (194 ISI, 149 GS)

Gorham ED, Garland CF, Garland FC. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. *Can J Public Health.* 1989 Mar-Apr;80(2):96-100. (48 GS)

Suda T. The role of 1 alpha,25-dihydroxyvitamin D3 in the myeloid cell differentiation. *Proc Soc Exp Biol Med.* 1989 Jul;191(3):214-20.



Miyaura C, Onozaki K, Akiyama Y, Taniyama T, Hirano T, Kishimoto T, Suda T. Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1). *FEBS Lett.* 1988 Jul 4;234(1):17-21.



Manolagas SC. Vitamin D and its relevance to cancer. *Anticancer Res.* 1987 Jul-Aug;7(4A):625-38. (51 ISI)



Abe J, Moriya Y, Saito M, Sugawara Y, Suda T, Nishii Y. Modulation of cell growth, differentiation, and production of

interleukin-3 by 1 alpha,25-dihydroxyvitamin D3 in the murine myelomonocytic leukemia cell line WEHI-3. *Cancer Res.* 1986 Dec;46(12 Pt 1):6316-21.

Decarli A, La Vecchia C. Environmental factors and cancer mortality in Italy: correlational exercise. *Oncology.* 1986;43(2):116-26.

Nagakura K, Abe E, Suda T, Hayakawa M, Nakamura H, Tazaki H. Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. *Kidney Int.* 1986 Apr;29(4):834-40.



Chida K, Hashiba H, Fukushima M, Suda T, Kuroki T. Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3. *Cancer Res.* 1985 Nov;45(11 Pt 1):5426-30.

Facchini U, Camnasio M, Cantaboni A, Decarli A, La Vecchia C. Geographical variation of cancer mortality in Italy. *Int J Epidemiol.* 1985 Dec;14(4):538-48.

Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. *Lancet.* 1985 Feb 9;1(8424):307-9. (433 ISI ISI, 182 GS)

Kato I, Tajima K, Kuroishi T, Tominaga S. Latitude and pancreatic cancer. *Jpn J Clin Oncol.* 1985 Jun;15(2):403-13. (9 ISI)

Kuroki T, Chida K, Hashiba H, Hosoi J, Hosomi J, Sasaki K, Abe E, Suda T. Regulation of cell differentiation and tumor promotion by 1 alpha,25 dihydroxyvitamin D3. *Carcinog Compr Surv.* 1985;10:275-86.

Newell GR, Lynch HK, Gibeau JM, Spitz MR. Seasonal diagnosis of Hodgkin's disease among young adults. *J Natl Cancer Inst.* 1985 Jan;74(1):53-6.



Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. *J Cell Biol.* 1984 Feb;98(2):391-8. (416 ISI)

Miyaura C, Abe E, Suda T. Extracellular calcium is involved in the mechanism of differentiation of mouse myeloid leukemia cells (M1) induced by 1 alpha, 25-dihydroxyvitamin D3. *Endocrinology.* 1984 Nov;115(5):1891-6.



Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, Nishii Y, DeLuca HF, Suda T. 1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. *Proc Natl Acad Sci U S A.* 1983 Jan;80(1):201-4. (249 ISI)

Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. *Endocrinology.* 1983 Dec;113(6):1950-7. (353 ISI)

Hozumi M. Fundamentals of chemotherapy of myeloid leukemia by induction of leukemia cell differentiation. *Adv Cancer Res.* 1983;38:121-69. Review. (206 ISI)

McCarthy DM, San Miguel JF, Freake HC, Green PM, Zola H, Catovsky D, Goldman JM. 1,25-dihydroxyvitamin D₃ inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. *Leuk Res.* 1983;7(1):51-5. (329 ISI)

Murao S, Gemmell MA, Callahan MF, Anderson NL, Huberman E. Control of macrophage cell differentiation in human promyelocytic HL-60 leukemia cells by 1,25-dihydroxyvitamin D₃ and phorbol-12-myristate-13-acetate. *Cancer Res.* 1983 Oct;43(10):4989-96. (139 ISI)

Shiina Y, Abe E, Miyaura C, Tanaka H, Yamada S, Ohmori M, Nakayama K, Takayama H, Matsunaga I, Nishii Y, DeLuca HF, Suda T. Biological activity of 24,24-difluoro-1 alpha, 25-dihydroxyvitamin D₃ and 1 alpha, 25-dihydroxyvitamin D₃-26,23-lactone in inducing differentiation of human myeloid leukemia cells. *Arch Biochem Biophys.* 1983 Jan;220(1):90-4.

Tanaka H, Abe E, Miyaura C, Shiina Y, Suda T. 1 alpha,25-dihydroxyvitamin D₃ induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. *Biochem Biophys Res Commun.* 1983 Nov 30;117(1):86-92. (171 ISI)



Tanaka H, Abe E, Miyaura C, Kuribayashi T, Konno K, Nishii Y, Suda T. 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). *Biochem J.* 1982 Jun 15;204(3):713-9. (405 ISI)



Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D₃. *Proc Natl Acad Sci U S A* 1981;78:4990-4. (825 ISI, 146 GS)

Colston K, Colston MJ, Feldman D. 1,25-Dihydroxyvitamin D₃ and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. *Endocrinology* 1981;108:1083-6. (294 ISI)

Miyaura C, Abe E, Kuribayashi T, Tanaka H, Konno K, Nishii Y, Suda T. 1 alpha,25-Dihydroxyvitamin D₃ induces differentiation of human myeloid leukemia cells. *Biochem Biophys Res Commun.* 1981 Oct 15;102(3):937-43.



Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? *Int J Epidemiol.* 1980 Sep;9(3):227-31. (189 ISI)



Eisman JA, Martin TJ, MacIntyre I, Moseley JM. 1,25-dihydroxyvitamin-D-receptor in breast cancer cells. *Lancet.* 1979 Dec 22-29;2(8156-8157):1335-6. (117 ISI)

Murphy LC, Wild J, Posen S, Stone G. 25-Hydroxycholecalciferol receptors in human breast cancer. *Br J Cancer.* 1979 May;39(5):531-5.

Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979;20:1188–90. (391 ISI)



Apperly FL. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941;1:191–5. (43 ISI)



Peller S, Stephenson CS. Skin irritation and cancer in the United states Navy. Am J Med Sci: 1937;194:326-333. (29 ISI citations) (if not stated, is ISI; GS refers to Google Scholar)